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ABSTRACT 
 
MARTIN WHITTLE: Targeting the Triple-Negative Breast Cancer Kinome with Chemical 
Proteomics  
(Under the direction of Dr. Gary Johnson) 
 
Kinases are members of a large dynamic and cooperative signaling network, 
which senses inhibition of key nodal kinases and induces compensatory responses that 
offset pharmacological intervention. Combination therapies that target multiple growth- 
and survival promoting kinases are proving to be a better strategy for successful cancer 
therapy. What is lacking is the ability to measure whole kinome activity and to assess 
kinome adaptation and resistance to targeted therapies. We have developed a chemical 
proteomics approach that couples kinase affinity capture with quantitative mass 
spectrometry, providing a systems biology platform to profile global kinome activity in 
cancer cells, GEMM tumors and patient biopsies. Our chemical proteomic approach 
captures the majority of the expressed kinome estimated by RNA-seq and detects 
altered kinome activity profiles in response to stimulus or kinase inhibitors. Kinases from 
all major kinome subfamilies are captured with a large percentage representing the 
understudied kinome. Applying this technology, we discovered previously undefined 
activation of tyrosine and serine/threonine kinases in breast cancer cell lines in response 
to targeted inhibitors against MEK or EGFR that are currently undergoing clinical trials. 
Combined kinome activity assessment using chemical proteomics and RNAi synthetic 
lethal screens predicted a specific kinase inhibitor combination therapy. The combination 
therapy gave apoptosis and tumor regression in a breast cancer GEMM, where single 
agents were largely ineffective.  The relevance of kinome reprogramming to patient 
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triple-negative breast cancer was confirmed by the investigation of MEK inhibitor-treated 
patient samples from a window trial established in conjunction with GlaxoSmithKline.  
However, differential kinome responses were observed across intrinsic breast cancer 
subtypes, suggesting that broader approaches to targeting or preventing kinome 
reprogramming may be necessary to avert resistance to kinase inhibitor therapies.  The 
findings presented here define a novel approach to determining kinome-based 
mechanisms of resistance to targeted therapies to suggest novel inhibitor combinations 
and strategies that may more effectively treat triple-negative breast cancer. 
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I.    INTRODUCTION 
 
Breast cancer presentation and treatment 
Breast cancer is a global health concern that accounts for approximately 29% of 
cancer diagnoses and 14% of cancer deaths in women each year, and is the most 
prevalent and second deadliest form of cancer in women1.  Greater than 40,000 breast 
cancer-related deaths in the United States are expected during the year 2013 alone, 
despite improvements in early detection and treatment options contributing to a steady 
decline in US breast cancer mortality rates since 1989.  Not surprisingly, the largest 
factor contributing to long-term survival of breast cancer patients is the tumor stage at 
diagnosis.  Patients presenting with localized disease have a 5-year survival rate of 
99%, compared to a 23% 5-year survival of patients presenting with distant metastases2.  
The majority (60%) of patients are diagnosed with localized diseased, 33% show 
regional cancer cell invasion, and 5% of patients present with metastatic disease (2% 
are unstaged).  Treatment options vary depending on stage at presentation and tumor 
subtypes, but a combination of surgery and adjuvant chemotherapy and/or radiation 
therapy is common as a first line for breast cancer treatment3.  Targeted systemic 
therapies that inhibit specific growth- and survival-promoting molecular targets provide 
another course of therapy where surgery/chemotherapy is unlikely to succeed. 
Several targeted therapies have been approved by the Food and Drug 
Administration (FDA) for use in the treatment of breast cancer, most of which target 
either HER2, estrogen receptorα/β (ER), or aromatase (which is responsible for estrogen 
synthesis).  These targeted therapies are indicated for breast cancers which exhibit high 
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expression of HER2 or hormone receptor (ER/progesterone receptor (PR)). Triple-
negative breast cancers (TNBC), which comprise approximately 15% of all breast 
cancers, are ER-negative, PR-negative, and lack HER2 overexpression, and thus do not 
respond to HER2-targeted or hormonal therapy4–6.  While TNBCs are often initially 
sensitive to chemotherapy, tumors almost invariably reappear with a more aggressive 
phenotype that is resistant to further treatment7.  A poor understanding of the oncogenic 
drivers and resistance mechanisms in TNBC has hindered the development and 
approval of molecularly targeted therapies in this setting, leaving few options to combat 
TNBC after the failure of chemotherapy.   
 
TNBC and intrinsic breast cancer subtypes 
While the term “triple-negative” is clinically convenient, a more accurate 
classification of breast cancer is provided by gene expression analysis, which shows a 
clear demarcation of five intrinsic subtypes of breast cancer across a large array of 
patient tumors8.  HER2-enrichment defines one subtype, and hormone receptor positive 
breast cancers are predominantly classified into the luminal A and luminal B subtypes.  
The vast majority of TNBCs cluster distinctly into either the basal-like (BL) or claudin-low 
(CL) subtypes, which comprise 11-23% and 7-11% of breast cancers, respectively8.  
Despite sharing negativity for HER2, PR, and ER, distinct genetic signatures 
discriminate basal-like cancers from claudin-low.  Particular differences can be observed 
in the expression of cell signaling mediators, such as kinases and their regulators, 
suggesting an intrinsic divergence in growth and survival signaling.  For instance, 
expression of the receptor tyrosine kinases (RTKs) VEGFR2, PDGFRβ, DDR2 or AXL 
are significantly associated with claudin-low cell lines and tumors as compared to basal-
like TNBC8.   
Analysis of subtype-specific gene signatures proposes a hierarchy of breast 
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cancer differentiation that parallels normal mammary development, where claudin-low 
cancers precede basal-like cancers as the least differentiated of breast cancer 
subtypes9.  Overall, claudin-low tumors and cell lines exhibit mesenchymal and stem-like 
gene expression patterns, whereas basal-like breast cancers are more differentiated and 
express epithelial markers8,9.  The claudin-low subtype is also highly enriched for breast 
cancers having the CD44+/CD24-/low gene signature that is characteristic of drug-
resistant tumor-initiating cells10.  The acquisition of claudin-low mesenchymal 
characteristics may result from an epithelial to mesenchymal transition (EMT), an 
important developmental process which can be reactivated in cancer cells to promote 
cell invasiveness, motility, stemness, and drug resistance11.  With increased drug 
resistance provided by the claudin-low phenotype, treatment of patient tumors with 
hormone therapy or chemotherapy can select for claudin-low cancer cells from a 
heterogeneous tumor environment, leading to the outgrowth of aggressive claudin-low 
cancers from previously basal, luminal, or HER2-amplified breast cancers10,12.   
Taken together, the divergence of basal-like and claudin-low gene expression 
patterns and differentiation hierarchies, coupled with associated differences in cell 
signaling and drug responsiveness, underscore the importance of distinguishing 
between basal-like and claudin-low cancers when designing pre-clinical studies or 
clinical trials for TNBC.  Unique targeted therapies will likely be needed to treat these 
distinct breast cancer subtypes when chemotherapy/surgery fails.  Perhaps the most 
tractable gene family for the development of targeted inhibitors is the kinome, due to the 
established role of kinases in mediating oncogenic signaling and the relative ease of 
targeting kinases with small molecule and antibody inhibitors. Understanding kinase 
signaling in the distinct contexts of basal-like and claudin-low breast cancers will be 
important for defining effective targeted therapies for TNBC13. 
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Targeting kinases for cancer therapy 
The human kinome consists of 518 protein kinases that mediate cellular signal 
transduction by catalyzing reversible and site-specific phosphorylation of diverse protein 
substrates.  As one of the largest enzyme classes, encompassing 1.7% of the human 
genome, kinases collectively phosphorylate an estimated one-third of all proteins14,15.  
Phosphorylation on serine, threonine, or tyrosine residues can cause a shift in substrate 
conformation, often triggering biochemical changes to such properties as localization, 
protein interactions, or activity of the substrate.  This process is reversed by protein 
phosphatases, which catalyze the hydrolysis of phosphoryl groups from amino acid 
residues.  The kinase domain, which is well-conserved across distinct kinase families, is 
folded into an N-terminal and C-terminal lobe.  ATP binds with varying affinities (Km
ATP 
ranging from ~1-1000 nM for different kinases) in a pocket between the two lobes, and is 
coordinated by several highly conserved residues.  Among these, a glutamate residue 
(Glu91 for PKA) that lies on the so-called α-C helix (within the N-lobe) functions as an 
ion pair with a critical N-lobe lysine (PKA Lys72) that coordinates the α and β 
phosphates of ATP16.  Conformational changes to the α-C helix can affect ATP binding 
and thus kinase activity.  For many kinases, enzymatic activity is largely contingent upon 
the phosphorylation state of a conserved activation segment that runs across the cleft 
between the lobes, termed the activation loop17.  Phosphorylation on this loop, by 
autocatalysis or a separate regulatory kinase, can increase kinase activity through 
conformational shifts that augment substrate and/or ATP binding18–20.  When the 
activation loop is properly oriented to allow substrate and ATP binding, transfer of the -
phosphate of ATP to the substrate serine, threonine, or tyrosine residue is stabilized by 
divalent cations (themselves coordinated by several conserved asparagine and 
aspartate residues) that serve as cofactors in the phosphoryl transfer reaction.   
Targeting kinases for cancer therapy has been a driving force in the development 
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of new treatment strategies across a wide range of cancer types.  Greater than 15 small 
molecule and antibody inhibitors against kinases have been approved by the FDA for 
cancer therapy, with many more in the developmental pipeline.  The majority of these 
approved inhibitors target RTKs due to the common occurrence of aberrant RTK 
signaling in many cancers.  Most small molecule kinase inhibitors compete with ATP for 
the conserved ATP-binding cleft between lobes of the kinase domain.  ATP-competitive 
kinase inhibitors that preferentially bind the activated kinase conformation are classified 
as type I kinase inhibitors, which are usually identified by functional assays using 
activated kinases and mimic ATP by interacting with similar residues within the kinase 
domain13.  Type II kinase inhibitors, such as the HER2/EGFR inhibitor lapatinib, 
additionally bind to a hydrophobic pocket adjacent to the ATP-binding cleft and are 
indirectly competitive with ATP in that they bind and stabilize an inactive kinase 
conformation (DFG-out) that has a lower affinity for ATP21.  Kinase inhibitors can also 
bind allosterically, at sites distant from the ATP-binding pocket, inducing conformational 
changes and/or blocking oligomerization to render the kinase inactive.  Allosteric 
inhibitors are classified as type III, and are usually highly specific because they bind 
outside the conserved kinase ATP-binding pocket and at regions that may be more 
unique to the targeted kinase, although few examples exist.  The MEK1/2 inhibitor 
AZD6244 is an example of a type III kinase inhibitor.   
Distinct cellular processes, including growth, metabolism, stress response, 
movement, and apoptosis are regulated by protein phosphorylation, and tight control of 
kinase activity is required for proper function of these cellular programs.  Aberrant kinase 
signaling, whether by kinase overexpression, mutation, or dysregulation, has been 
shown to be central to the proliferation and survival of many cancer types.  Constitutive 
kinase activity can drive cancer progression through hyperactivation of growth signaling 
pathways, suppression of apoptosis, angiogenesis, and other mechanisms.  In such 
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instances where cancer cell growth and survival hinges upon constitutive kinase activity, 
small molecule inhibition of the activated kinase is often an effective course of therapy.  
For instance, targeting the BCR-ABL fusion protein that characterizes chronic 
myelogenous leukemia (CML) with small molecule inhibitors (i.e. imatinib, nilotinib) 
strongly suppresses cancer cell proliferation and leads to remission in a majority of CML 
patients22.  Additionally, targeting HER2 with lapatinib and/or trastuzumab has increased 
disease-free and overall survival in the setting of HER2-amplified breast cancer23.  
Despite the critical role of kinases in mediating cancer signal transduction, much of the 
kinome is virtually unstudied and many kinases lack targeted inhibitors24. 
Oncogenic growth signaling often begins with aberrant expression and/or 
activation of RTKs at the cell surface.  RTKs are generally composed of an extracellular 
ligand-binding domain with specificity towards external growth factors and cytokines, a 
transmembrane domain and intracellular tyrosine kinase domain.  Ligand binding 
commonly induces homodimerization or heterodimerization of the receptor, whereupon 
conformational shifts allow transphosphorylation of receptors at multiple tyrosine 
residues, often including the activation loop.  Phosphotyrosine residues on RTKs are 
subsequently recognized by a wide array of proteins with conserved phosphotyrosine-
binding domains (such as the SH2 domain) that directly mediate intracellular signaling or 
serve as adaptors for other signaling effectors.  Specificity of the recruited proteins 
depends upon the protein sequence on the C-terminal side of the tyrosine 
phosphorylation, thus providing distinction to the signaling pathways activated by each 
phosphorylation site and receptor25.  For example, activation of the RTK EGFR begins 
by binding of its cognate ligands (EGF, TGFα or amphiregulin), followed by 
homodimerization or heterodimerization with related paralogs HER2, HER3, or HER4.  
While dimerization leads to transphosphorylation in each case, dimerization with 
different partners elicits unique effects due to the phosphorylation of diverse tyrosine 
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residues on each receptor.  Phosphorylation of EGFR on Y1068 leads to recruitment of 
GRB2, which serves as an adaptor to recruit the Ras guanine nucleotide exchange 
factor SOS to the membrane.  SOS subsequently interacts with membrane-bound Ras 
to promote GTP binding and Ras activation.  Similarly, phosphorylation of HER3 at 
Y1289 recruits the p85 subunit of PI3K, bringing along the catalytic p110 subunit to the 
membrane and in close proximity to its phosphoinositol substrates.  In cancer, 
constitutive activation of EGFR and/or other RTKs causes hyperactivation of these and 
other growth signaling pathways. 
 
Targeting the RAF-MEK-ERK pathway in breast cancer 
 Oncogenic tyrosine kinases (TKs) and RTKs often feature as drivers of 
tumorigenesis and tumor progression, but the prominent role of activated ERK signaling 
in cancer cell growth and survival has made the RAF-MEK-ERK axis a major focus for 
targeted cancer therapies downstream of RTKs.  This pathway is a canonical mitogen-
activated protein kinase (MAPK) pathway that relays proliferation signals from upstream 
RTKs/Ras to the nucleus, where ERK1/2 (the terminal MAPKs) act on a wide array of 
transcription factors to promote proliferation and survival (Figure 1.1).  The RAF-MEK-
ERK pathway is hyperactivated in most cancers, often occurring through 
mutation/overexpression of diverse RTKs or oncogenic mutations in Ras or RAF.  There 
are three RAF proteins (ARAF, BRAF and CRAF) that operate as MAP3Ks in this 
module.  RAFs are serine/threonine kinases that are recruited by activated Ras to the 
plasma membrane, where they become active by dimerization and association with 
scaffolding proteins.  Once activated, RAFs phosphorylate the MAP2Ks MEK1 and 
MEK2 on two conserved activation loop serines to induce conformational shifts leading 
to MEK activation.  MEK1/2 subsequently phosphorylate the terminal MAPKs, ERK1/2, 
on threonine and tyrosine residues within their activation loops.  Activated ERK1/2 can 
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dimerize to phosphorylate cytoplasmic substrates or translocate to the nucleus as 
monomers to phosphorylate nuclear targets26.  While the substrates of MEK1/2 are 
essentially confined to ERK1/2, over 160 substrates (predominantly nuclear) have been 
identified for ERK1/2, including several well-known oncogenes (such as c-MYC) and 
tumor suppressors (such as BIM) that are phosphorylated by ERK1/2 to alter protein 
stability and/or function27.  In the context of cancer cells, activated ERK1/2 promote cell 
cycle progression and evasion of apoptosis by acting on such substrates, although in the 
context of untransformed primary cells hyperactivation of ERK1/2 can lead to oncogene-
induced senescence through ERK1/2-mediated activation of p38 MAPK28.  Very little is 
known about the unique substrates and roles of MEK and ERK paralogs, largely due to 
high homology and the lack of reagents to discern between their phosphorylation and/or 
activity. 
 An array of targeted therapeutics has been developed against RAF-MEK-ERK 
pathway components.  Vemurafenib and dabrafenib, ATP-competitive inhibitors targeting 
mutant BRAF(V600E), yield a striking regression of metastatic melanoma harboring 
mutant BRAF before an invariable resistance and tumor reemergence29–31.  Targeting 
wildtype RAF with small molecule inhibitors leads to paradoxical activation of RAF due to 
drug-induced dimerization, causing concern for the applicability of RAF inhibitors to treat 
diverse cancer types.  In this light, MEK is considered a more broadly targetable 
component of the RAF/MEK/ERK pathway, and several allosteric MEK1/2 inhibitors 
(MEKi), including GSK1120212, AZD6244, U0126, CI-1040 and PD0325901, have 
reached various stages of clinical development.  These inhibitors generally exhibit very 
high selectivity due to the targeting of a MEK-specific allosteric site adjacent to the ATP-
binding pocket.  Binding at this site stabilizes MEK1 in an inactive conformation while still 
allowing ATP to bind in the catalytic pocket32.  Interestingly, phosphorylation of the 
MEK1/2 activation loop reduces the affinity of GSK1120212 for MEK1/2 by 12- to 20-
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fold, suggesting that activated upstream signaling may promote resistance to MEK1/2 
inhibitors by reducing drug potency33.  Other allosteric MEK1/2 inhibitors have 
recapitulated such phosphorylation-dependent affinity for MEK34.    A highly selective 
ATP-competitive ERK1/2 inhibitor, SCH772984, is also under development at Merck that 
shows promise for the treatment of melanoma and colorectal cancer cell lines with 
acquired resistance to RAF and/or MEK inhibitors35.  The ability to target multiple 
kinases in this pathway may be important to prevent reactivation of RAF/MEK/ERK 
signaling and drug resistance36. 
Many studies have highlighted the importance of the RAF-MEK-ERK pathway in 
cell proliferation and survival of breast cancer.  Expression and activation of MAPK 
pathway components are significantly higher in breast tumor samples compared to 
matched normal tissue, validating this pathway as a target in breast cancer37–39.  In vitro 
studies have shown that treatment of various breast cancer cell lines with the MEKi 
U0126 slows proliferation, increases apoptosis and sensitizes cells to anoikis40,41.  
Interestingly, basal-like TNBC cell lines generally exhibit greater sensitivity to MEKi 
compared to luminal or HER2-amplified breast cancer lines (claudin-low not considered), 
possibly due to greater activation of RAS/RAF/MEK pathway signaling in this subtype42–
44.  Expression of the ERK phosphatase DUSP6 also contributes strongly to MEKi 
sensitivity, and expression of a related ERK phosphatase, DUSP4, leads to reduced 
ERK activity and improved outcomes after neoadjuvant chemotherapy in basal-like 
breast cancer patients43,45.  Studies by Balko, et al. and MacKeigan, et al. have further 
revealed that the addition of MEKi to taxol-based chemotherapeutics causes synergistic 
induction of apoptosis in breast cancer cell lines and tumors45,46.   
Despite the apparent importance of RAF/MEK/ERK activity in breast cancer, 
clinical trials with single-agent MEK inhibitors have so far yielded disappointing 
results47,48.  Mutations to MEK that prevent inhibitor binding have been described, but it 
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is likely that tumor cells also develop resistance to MEK inhibitors through other 
mechanisms of pathway reactivation49,50.  Phosphorylation of MEK1/2 by upstream 
kinases leading to reduced MEKi affinity could theoretically contribute to intrinsic MEKi 
resistance, leading to reduced efficacy of single-agent MEKi treatments.  Thus, 
activation of alternative kinases, both upstream and/or parallel to the RAF/MEK/ERK 
pathway, may sustain cancer cell growth/survival in the presence of MEKi.  In support of 
this, combination therapies with MEK inhibitors have shown promise in preclinical cancer 
models51.  These studies make it clear that greater understanding of the mechanisms 
behind MEKi resistance is needed for the development of efficacious MEKi-based 
therapies to treat breast and other cancers. 
 
Kinome resilience and adaptation to targeted inhibition 
Though kinases are often studied singularly or as members of linear pathways, 
kinases integrate into convoluted signaling cascades and networks that relay and 
integrate diverse cell signals.  RAF-MEK-ERK signaling exemplifies this plasticity, where 
pathway activity is modified by diverse upstream kinases, phosphatases responsive to 
pathway activity, and internal feedback phosphorylation on RAF and MEK1 (from MEK 
and ERK, respectively).  Unfortunately, this resiliency of the kinome has made single-
agent kinase inhibitor cancer treatment extremely difficult.  Mutation at a conserved 
“gatekeeper” residue in the ATP binding pocket (such as T790M in EGFR) can provide 
drug resistance by sterically hindering drug binding, making the mutant kinase 
insensitive to previously effective drug doses52.  Cancer cells can circumvent targeted 
kinase inhibition to reactivate growth signaling through such mutations and/or 
amplification of the targeted kinase, activation of alternative pathways, or pathway 
reactivation through other methods (Figure 1.2)53.  Such diverse mechanisms of 
adaptive resistance to kinase inhibitors have been described in a variety of cancer types.   
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A prominent example of kinase inhibitor resistance is seen in malignant 
melanomas, where oncogenic mutation in the kinase BRAF are common54.  The most 
frequent BRAF mutation in melanoma is the V600E mutation and this primarily results in 
chronic activation of the MEK/ERK pathway to promote cell growth.  Consequently, small 
molecule inhibitors of mutant RAF are attractive therapeutics for the treatment of 
melanoma and other RAF-driven cancers55.  Interestingly, multiple studies uncovered a 
surprising paradoxical resistance of RAF kinase signaling to select RAF inhibitors56–58.  
RAF kinase inhibitors (PLX4720, sorafenib and 885-A), while highly effective at inhibiting 
mutant BRAF, activated wild-type RAF through inhibitor-mediated dimerization57.  This 
compensatory activation is dependent on inhibitor binding to the ATP site of one RAF 
molecule, which stimulates dimerization and activation of the drug-free RAF protomer.  
Thus, despite efficacy at inhibiting mutant BRAF in tumors, RAF inhibitors pose a risk of 
enhancing Ras-dependent tumors through activation of wild-type RAF.  Moreover, N-
Ras mutation or up-regulated PDGFRβ expression were also shown to accompany the 
resistance of cells to PLX403254.  As suggested from these findings, strategies to co-
target both RAF and MEK simultaneously have demonstrated improved growth inhibition 
and suppression of RAF-MEK-ERK pathway activation and prolonged disease-free 
survival in patients49,59–61.  Other groups have shown that combining MEK and/or 
PI3K/mTOR prevented the acquired resistance to the BRAF inhibitor GSK2118436, 
suggesting that co-targeting these two pathways is also a viable strategy62,63.  While 
such studies provide an important cautionary example of the unexpected changes in the 
kinome in response to single kinase inhibitors, they also illustrate the importance of 
elucidating kinome responses to select inhibitors.   
Another example of kinome feedback adaptation has been gleaned from studies 
on PI3K and AKT inhibitors.  Of central importance is the role of feedback regulation of 
the mTOR pathway64.  Rapamycin-dependent inhibition of mTOR complex 1 (mTORC1) 
12 
 
relieves feedback regulation of IGF1R, thereby triggering a compensatory activation of 
IGF1R and AKT targets such as the transcription factor FOXO65,66.  Furthermore, 
Chandarlapaty et al. showed that inhibition of PI3K/AKT relieved feedback inhibition and 
increased the expression of a unique set of receptor tyrosine kinases including HER3, 
IGF1R and INSR67.  In addition to expression, the phosphorylation of multiple RTKs was 
also stimulated by AKT inhibition.  Treatment of cells with AKT inhibitors resulted in up-
regulation of RTK transcripts in a FOXO-dependent manner.  Given the significance of 
this RTK response, the authors tested the combination of HER kinase inhibitors 
(lapatinib and Iressa) with AKT inhibitors in xenograft models and showed that the 
combination of these inhibitors was highly effective at inhibiting tumor growth.  
Chakrabarty et al. also showed that inhibition of PI3K with the small molecule inhibitor 
XL147 upregulated the expression and activation of multiple RTKs, including HER3, in a 
manner dependent on HER268.  Again, co-targeting the RTK response with trastuzumab 
or lapatinib was synergistic at inhibiting growth, compared with the action of these 
inhibitors alone.  These studies exemplify the importance of elucidating the kinome 
feedback mechanisms and understanding their implications for successful therapeutic 
applications.   
Activation or mutation of the EGFR and downstream kinase pathways is common 
in glioblastoma multiforma (GBM), colorectal cancer, non-small-cell lung carcinoma 
(NSCLC) and TNBC69.  This is often a result of EGFR mutations or overexpression, 
hence EGFR inhibitors have been investigated as possible therapeutics in these 
settings, with limited success70,71.  Studies now demonstrate the difficulty of targeting this 
RTK is due to either secondary gatekeeper mutations (T790M) that prevent EGFR 
inhibition or from activation of alternative RTKs following loss of EGFR activity.  In 
particular, several studies in EGFR-mutant NSCLC identify MET amplification and 
activation as a mechanism for resistance to EGFR inhibitors, where MET amplification is 
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observed in 15–22% of NSCLC patient’s tumors that were resistant to EGFR 
inhibitors72,73.  Multiple lines of evidence suggest that activated MET can compensate for 
EGFR inhibition by partially protecting against loss of phospho-EGFR and contributing to 
sustained activation of downstream growth signaling through ERK and AKT.  A direct 
association between EGFR and MET has been observed, although it is unclear how this 
heterodimerization contributes to EGFR inhibitor resistance74.  In such cases where MET 
is induced as a mechanism of EGFR inhibitor resistance, cotreatment with EGFR and 
MET inhibitors synergistically inhibited proliferation of cell lines, prevented tumor growth, 
and induced apoptosis in cell and tumor models.  Similar studies demonstrate the 
remarkable plasticity of MET signaling in response to expression of EFGR mutations 
(de2-7 EGFR) in GBM75.  While it has been shown that EGFR inhibitor treatment can 
select for cells with pre-existing MET amplification, it is also evident that loss of EGFR 
activity can rapidly induce compensatory expression/activation of MET and other 
tyrosine kinases, including FGFR2 and Src-family kinases (SFKs)76–79.  This induced 
kinase activity is independent of genetic mutation or amplification, and likely results, in 
part, from loss of negative-feedback regulation of suppressed kinases.  Additionally, 
acute loss of upstream kinase signaling can trigger changes in transcription factor 
stability and/or activity that lead to induced expression of RTKs and their ligands.  This 
was exemplified by Ware et al., who defined loss of ERK activity downstream of EGFR 
inhibition as causal in de-repression of FGFR2/3 expression in NSCLC cell lines77.   
Some examples of kinome adaptation to targeted inhibitors in breast cancer have 
also been described.  In HER2-amplified breast cancers, inhibition of HER2 with the 
monoclonal antibody trastuzumab yields a small but significant benefit in disease-free 
and overall survival, whereas treatment with the HER2-targeted small molecule inhibitor 
lapatinib provides only marginal improvement to disease-free survival80–82.  Combination 
of trastuzumab and lapatinib, which have differing mechanisms of inhibition, gives a 
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synergistic tumor inhibition in preclinical models and doubles the pathological complete 
response rate (pCR) to approximately 40% prior to surgery83.  However, this translates 
to only a 5-month improvement to median overall survival, sparking several studies to 
understand why near-complete inhibition of HER2, considered to be the major driver in 
these cancers, yields only a modest tumor response in vivo84.  One major mechanism of 
HER2-inhibitor resistance that has been characterized is upregulated expression and 
activation of other HER-family members such as EGFR and HER385,86.  Increases in 
HER3 mRNA transcript, protein abundance and protein phosphorylation can be 
observed within 48h of lapatinib treatment of HER2-amplified SKBR3 cells87.  This 
resulted from loss of AKT-mediated negative feedback regulation, and constitutively 
active AKT prevented HER3 upregulation following HER2 inhibition.  Increased 
expression of HER3, which is widely considered to be catalytically inactive, was 
proposed to enhance HER2-HER3 dimerization to mediate allosteric activation of HER2 
and subsequent reactivation of ERK and AKT.  This mechanism suggests that minimal 
residual HER2 activity may be sufficient to allow escape from inhibition to redrive growth 
signaling pathways, especially where dose-limiting toxicities prevent absolute inhibition.  
These studies have led to the development of the monoclonal antibody pertuzumab, 
which binds the dimerization domain of HER2 to prevent receptor dimerization (unlike 
trastuzumab, which binds to prevent ligand-independent mitogenic signaling).  
Combination of trastuzumab and pertuzumab was shown to synergistically inhibit tumor 
growth in preclinical models and provide a significant benefit for overall and disease-free 
survival in clinical trials88,89.  The importance of HER-family reprogramming as a 
mechanism of resistance to HER2-targeted therapies is clear, however, multiple groups 
have also revealed contributions of EPHA2, AXL, MET and IGF1R towards intrinsic 
and/or acquired resistance to targeted therapies in HER2-driven breast cancer90–93.  
These studies suggest that multiple mechanisms of kinome adaptation may 
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simultaneously contribute to resistance to targeted inhibitors, highlighting the need to 
understand exactly how targeted inhibitors influence kinome signaling. 
Such examples of kinome adaptation demonstrate the diverse mechanisms of 
plasticity and resistance in the kinome of tumor cells under the selective pressure of 
targeted kinase inhibitors.  With most oncogenic RTKs driving cell growth through 
conserved kinase signaling pathways, there is a high potential for cancer cells to 
circumvent targeted kinase inhibition by induced expression or activity of alternative 
kinases.  The high plasticity and resiliency of the kinome suggests that drug 
combinations targeting multiple kinase signaling pathways or nodes may be a more 
effective strategy to treat cancers driven by aberrant kinase signaling94.  Anticipating the 
mechanisms of drug response in cancer cells will help to prevent the persistence and 
selection of resistant populations from a heterogeneous tumor environment95.  Taken 
together, these studies highlight the need for standard methods to study kinome network 
signaling in the context of drug response and resistance.   
 
Application of chemical proteomics to study the kinome 
The philosophy of studying the kinome as a network of kinases or ‘kinomics’ was 
first proposed by Johnson and Hunter in 200596.  Initial efforts to study the kinome 
focused on identifying kinase substrates through large-scale phosphoproteomic 
analyses97.  However, because of the massive complexity of the phosphoproteome, 
these studies have provided only a partial insight into the detailed regulation of the 
kinome98.  Some studies have attempted to characterize the kinome through kinase 
activity assays99.  However, a limitation to this approach is the considerable assay 
development required to profile large-scale changes in kinase activity.  Recently, 
advances in proteomics and genomics technologies have revolutionized the analysis of 
the human kinome itself as an entity.  RNA-seq analysis revealed that approximately 
16 
 
70% of the total kinome (370/518) is expressed in typical breast cancer cell lines100,101.  
Other studies performed extensive profiling of expressed kinases in a large numbers of 
tissues or specific cancers102,103.   
Despite this information, important questions remain.  For instance, how many of 
these kinases are active and how does the activity of the kinome change in response to 
different stimuli or inhibitors? Moreover, how does one study the untargeted or 
understudied members of the kinome where well-characterized reagents are lacking?  
Increasing evidence of kinome plasticity as a mechanism of drug resistance has made 
understanding kinome network signaling a priority for cancer research.  Fortunately, 
advances in kinase enrichment and proteomics have greatly facilitated the ability to 
study the kinome at the protein level104.  On the basis of the original method of Haystead 
et al. using -phosphoryl-linked ATP affinity columns to capture kinases, Knockaert et al. 
were the first to demonstrate the utility of immobilized kinase inhibitors105–107.  Daub and 
co-workers refined this approach by using a broad range of immobilized kinase inhibitors 
coupled to Sepharose beads108.  An inherent advantage of the latter approach is the 
nanomolar affinity binding of kinases to the inhibitor beads, thereby permitting efficient 
capture of a large fraction of the kinome.  In addition, by increasing the variety of the 
coupled inhibitors, a greater diversity of kinases could be captured109.   
Initially this technology was used to profile kinase inhibitor selectivity and identify 
new cellular targets for select kinase inhibitors such as SB203580, gefitinib, SU6668 and 
others110–113.  Termed ‘kino-beads’, this method was commercialized (Axxima, Cellzome, 
Ambit) and broadly applied to assess kinase inhibitor specificity across the kinome 
109,114–117.  For example, Bantscheff et al. performed quantitative analysis of the kinase 
targets for imatinib, dasatinib and bosutinib in K562 leukemia cells116.  Similar studies 
have compared the selectivity of nilotinib and second-generation dual ABL/SFK (SRC 
family kinase) inhibitors118,119.  Others used this technology to compare the binding 
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affinity of 38 kinase inhibitors across a panel of 317 kinases117.  Importantly these papers 
marked some of the first studies to evaluate the specificity of structurally distinct 
inhibitors against large numbers of kinases.  The results of these and other studies 
demonstrated exquisite specificity for some inhibitors (lapatinib), whereas others 
(staurosporine, sunitinib, lestaurtanib and dasatinib) lacked specificity and bound many 
kinases from various kinase families117,120.  More recent studies expanded this 
technology to profile changes in the kinome itself.  Multiple investigators have used this 
strategy to demonstrate cell-type-specific sets of expressed kinomes using the 
immobilized inhibitors combined with LC (liquid chromatography)-MS/MS (tandem MS), 
phosphoproteomics analysis and quantitative MS115,121,122.  In an interesting application, 
Daub et al. used this approach to profile the change in the kinome from S- and M-phase-
arrested cells123.  Specifically, the authors quantified over 219 kinases, detecting over 
1000 phosphorylation sites (including activation loops) and identifying multiple kinases 
not previously associated with mitotic progression.  It has further been shown that 
activated kinases bind with higher affinity to type I inhibitor beads (compared to 
analogous inactive conformations), likely due to greater accessibility of the ATP-binding 
pocket in the active conformation and the use of activated kinases in the development of 
type I kinase inhibitors116.  Taken together, these data suggest that immobilized kinase 
inhibitors may be used as a platform to profile kinome expression and activity. 
Importantly, these recently developed technologies for kinome enrichment and 
characterization could be applied as a discovery mechanism to define the dynamic 
activity of the kinome in response to inhibitors.  Typically studies of kinome adaptation 
have relied on immunoblotting of select kinases or the use of phosphoantibody arrays to 
assess kinome changes124.  However, these methods are limited by phosphoantibody 
availability and specificity, and therefore limit the scale of analysis.  Affinity 
chromatography with immobilized pan-kinase inhibitors followed by quantitative mass 
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spectrometry allows for a more unbiased assessment of changes in kinase expression 
and activity after drug treatment.  A major application of this technique would be to 
define mechanisms of adaptive resistance from the kinome reprogramming response, 
providing a method for the rational design of inhibitor combinations with greater efficacy 
for cancer treatment. 
 
Objectives for this project 
 Currently, there are no standard methods for the rational design of targeted 
inhibitor combinations for cancer treatment.  Our first goal for this project was to design a 
method to systematically measure the kinome response to small molecule inhibitors 
(kinome reprogramming) in triple-negative breast cancer.  A precedent for the use of 
chemical proteomics for kinase enrichment and analysis of drug specificity or kinase 
expression has been established, but these techniques have not been applied to define 
drug-induced changes in kinome expression/activity.  We hypothesized that a chemical 
proteomic approach using immobilized kinase inhibitors can define novel kinase targets 
that are induced by the treatment of small-molecule inhibitors to MEK1/2 or HER2/EGFR 
(Figures 1.3A,B), which represent potentially important kinase targets in TNBC.  
Characterization of our multiplexed inhibitor-bead (MIB) strategy with mass spectrometry 
revealed substantial coverage of the expressed kinome across diverse kinase families.  
Basal-like and claudin-low TNBC subtypes were assessed individually, as the differential 
gene expression patterns indicated the likelihood of distinct kinome responses to 
targeted inhibitors.  The kinome reprogramming to diverse inhibitors was measured in 
order to define target-specific reprogramming events.  We also sought to define the 
mechanisms behind induced drug-induced kinase expression and activity. 
 We further posited that induced kinases may be supporting cancer cell 
proliferation and/or survival in the presence of inhibitor, and that targeting induced 
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kinases with additional small molecule inhibitors may attenuate drug resistance.  Our 
ultimate goal was the rational design of small molecule inhibitor combinations that exhibit 
greater efficacy for the treatment of triple-negative breast cancer patients.  To this end, 
kinases responding to targeted MEK or EGFR/HER2 inhibitors were targeted with RNAi 
or small molecule inhibitor combinations and assessed in cell growth assays to define 
those kinases contributing to growth/survival after MEK or EGFR/HER2 inhibition. 
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Figure 1.1 MEK/ERK signaling pathway.  Canonical ERK pathway signaling is shown.  
Activated RTKs (such as EGFR shown here) recruit factors leading to the activation of 
Ras at the plasma membrane.  Ras induces activity of the MAP3K RAF, leading to MEK 
and ERK activation.  ERK phosphorylates numerous substrates in the nucleus and 
cytoplasm to regulate transcription and growth/survival signaling.  Targeted inhibitors to 
MEK and EGFR (exemplified in red) are applied in this study. 
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Figure 1.2 Mechanisms of resistance to kinase inhibitors.  Demonstration of diverse 
mechanisms of resistance to kinase inhibitors is shown.  Kinase inhibitors (shown in 
blue) can be bypassed by mutation of gatekeeper and other residues, 
overexpression/amplification of the targeted kinase, or by activation of alternative growth 
signaling pathways through reprogramming. 
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Figure 1.3 Chemical structures of MEK and EGFR inhibitors.  A) Chemical structures 
of MEKi used in this study are shown.  B) Chemical structures of EGFR inhibitors used 
in this study are shown.
 
 
II.    MATERIALS AND METHODS 
 
Chapter III 
Cell culture 
HuMEC cells were grown in 5% FBS with HuMEC supplements.  MDA-MB-231 
and T2-C3Tag cells were grown in DMEM/F12 supplemented with 10% FBS.  SUM159 
cells were grown in DMEM/F12 supplemented with 5% FBS, 1 µg/ml hydrocortisone and 
5 µg/ml insulin.  MYL CML cells were cultured in RPMI 1640 medium supplemented with 
10% fetal bovine serum and 1% antibiotic/antimycotic.  SUM159-R cells were continually 
grown in the presence of 5 µM AZD6244.  For SILAC labeling, cells were grown for five 
doublings in arginine- and lysine-depleted media (as above) supplemented with either 
unlabeled L-arginine (42 mg/L) and L-lysine (71 mg/L) or equimolar amounts of 
[13C6,
15N4]arginine (Arg10) and [
13C6]lysine (Lys6) (Cambridge Isotope Laboratories).  
Proliferation was quantified by Cell-Titer Glo Luminescent Cell Viability Assay 
(Promega).  Media containing kinase inhibitors was replaced daily. 
 
Multiplexed inhibitor bead affinity chromatography 
Cells were lysed on ice for 20 minutes in lysis buffer containing 50 mM HEPES 
(pH 7.5), 0.5% Triton X-100, 150 mM NaCl, 1 mM EDTA, 1 mM EGTA, 10 mM sodium 
fluoride, 2.5 mM sodium orthovanadate, 1X protease inhibitor cocktail (Roche), and 1% 
each of phosphatase inhibitor cocktails 2 and 3 (Sigma).  Cell lysate was sonicated 
(3x10s) on ice and centrifuged for 15 min (13,000 rpm) at 4°C and the supernatant was 
collected and syringe-filtered through a 0.2 µM SFCA membrane.  The filtered lysate 
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 (approximately 20-40 mg of protein per experiment) was brought to 1M NaCl and pre-
cleared by flowing over 500 µl of blocked and washed NHS-activated Sepharose 4 Fast 
Flow beads (GE Healthcare).  The flow-through was collected and passed through a 
column of layered inhibitor-conjugated beads (Bisindoylmaleimide-X (50 µl), SB203580 
(50 µl), lapatinib (100 µl), dasatinib (100 µl), purvalanol B (100 µl), VI16832 (100 µl), 
PP58 (100 µl)) to isolate protein kinases from the lysates.  Kinase-bound inhibitor beads 
were washed with 20 ml of high-salt buffer and 10 ml of low-salt buffer, each containing 
50 mM HEPES (pH 7.5), 0.5% Triton X-100, 1 mM EDTA, 1 mM EGTA, and 10 mM 
sodium fluoride, and 1M NaCl or 150 mM NaCl, respectively.  A final wash of 1 ml 0.1% 
SDS was applied to the columns before elution in 1 ml of a 0.5% SDS solution in high 
heat.  Elutions from all columns were combined and cysteines were alkylated by 
sequential incubations with DTT (final concentration 5 mM) for 20 min at 60° C and 
iodoacetamide (final concentration 20 mM) for 30 min at room temperature in the dark.  
The elution was spin-concentrated to 100 µl and detergents were removed by a 
chloroform/methanol extraction.  Briefly, 400 µl of HPLC-grade methanol, 100 µl HPLC-
grade chloroform, and 300 µl HPLC-grade water was added to the 100 µl concentrated 
elution, with vortexing and centrifugation at 13,000 rpm between each addition.  After a 
final mixing, the sample was centrifuged for 5 min to pellet the protein at the interface 
and the upper phase was removed with care to leave the protein pellet intact.  The 
protein pellet and lower phase were resuspended in 300 µl of methanol, and the sample 
was again vortexed and centrifuged for 5 min to pellet the protein at the bottom of the 
tube.  The supernatant was removed and one or more methanol washes were performed 
to ensure the removal of detergents, resuspended in 50 mM ammonium bicarbonate (pH 
8) or 50 mM HEPES (pH 8) for SILAC or iTRAQ respectively.  Samples were digested 
overnight at 37°C with sequencing grade modified trypsin (Promega).  iTRAQ labeling of 
digested peptides was carried out using iTRAQ 4-plex reagent (AB SCIEX) for 2h at 
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room temperature in the dark.  Peptides were fractionated with Mini SCX Spin Columns 
and cleaned with PepClean C18 Spin Columns (Thermo Scientific) before separation by 
a Tempo LC MALDI Spotting System. 
 
MS analysis 
MS and MS/MS data were acquired with a MALDI TOF/TOF 5800 (ABSCIEX) 
and analyzed by ProteinPilot Software Version 3.0 (ABSCIEX) with a UniProtKB/Swiss-
Prot database.  Proteins were accepted when ≥1 unique peptide was identified at 99% 
confidence.  Peptide quantitation by ProteinPilot was performed using the Pro Group 
Algorithm and quant ratios are bias-corrected.  MIB/MS analysis with cell lines was done 
in 2-3 independent experiments.  A set of 3 independent experiments using SILAC 
labeled SUM159 cells treated with AZD6244 or DMSO was used to assess statistical 
significance and reproducibility of MIB/MS. 
 
qRT-PCR 
RNA was isolated from cell lines or murine tumors using the RNeasy® Plus Mini 
Kit (Qiagen).  qRT-PCR was performed on diluted cDNA with the Applied Biosystems 
7500 Fast Real-Time PCR System and inventoried TaqMan® Gene Expression Assays. 
 
In vivo tumorigenesis experiments 
Animal handling and procedures were approved by the UNC Institutional Animal 
Care and Use Committee and followed the NIH guidelines.  Male C3Tag mice were bred 
with wildtype females to produce experimental offspring.  Treatment began the same 
day a palpable mass was found.  Drugs were incorporated into chow and food was 
provided ab libitum.  Tumor size was assessed twice weekly by caliper measurements of 
tumor areas ((width)2 × length))/2 for 21d.  Percent change of tumor volume was 
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calculated using (Final volume – Initial Volume)/Initial Volume and graphed using R 
(http://www.r-project.org/).  Tumors at harvest were halved and either snap-frozen in 
liquid nitrogen and stored at -80C or placed in neutral buffered 10% formalin solution. 
 
Human breast tissue procurement 
All human breast tissue was obtained from the Tissue Procurement Facility in 
compliance with the laws and institutional guidelines as approved by the UNC IRB 
committee.  Clinical specimens were phenotyped by gene expression analysis in the lab 
of Chuck Perou. 
 
Generation of immortalized T2-C3Tag cell line from a C3Tag tumor 
An autochthonous tumor from a C3Tag mouse was excised and dissociated in a 
sterile fashion in the presence of 0.25% trypsin (Gibco).  Cells were then passed through 
a 40 micron cell strainer and grown in the presence of DMEM + 10% FBS.  Cells were 
isolated and expression of SV40T antigen verified by immunoblotting with antibodies 
specific to SV40 large T (EMD Biosciences, monoclonal, clone PAb416). 
 
Compounds 
Sorafenib and U0126 were purchased from LC Labs.  BEZ235 was purchased 
from Selleck; bisindoylmaleimide-X was from Alexis and purvalanol B was from Tocris.  
GSK3 Inhibitor X was obtained from Calbiochem.  Foretinib and AZD6244 were 
synthesized according to the procedures described in two patent applications 
(WO2005030140A2, WO2007002157A2).  PP58, VI16832, dasatinib, lapatinib, 
SB203580, PLX4720 and SB590885 were custom synthesized according to previously 
described methods by The Center for Combinatorial Chemistry and Drug Discovery, Jilin 
University, P.R. China123,125–128.   
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RNA sequencing 
Polyadenylated (poly-A) mRNA was isolated from 10 µg total RNA using Dynal 
oligo(dT) beads (Invitrogen).  Poly-A mRNA was fragmented for five minutes at 70C 
using Fragmentation buffer from Ambion.  First strand cDNA synthesis used random 
hexamer primers and SuperScriptII (Invitrogen).  Second strand cDNA synthesis was 
performed using DNApolI (Invitrogen) and was purified using QIAquick PCR spin 
columns (Qiagen).  Library preparation was performed according to manufacturer’s 
instructions (Illumina).   
 
RNA-seq alignment and transcript expression analysis 
76-bp Illumina RNA-seq reads for a claudin-low tumor (3 lanes), SUM159 (4 
lanes), and MDA-MB-231 (3 lanes) were obtained from the TCGA and aligned to the 
UCSC human knownGene mRNA from NCBI build 37 (hg19) using Bowtie129.  The 
alignment was performed allowing just one mismatch in each read and only the best 
resulting alignment was reported for each aligned read.  Duplicate reads were removed 
using Picard (http://picard.sourceforge.net) and in-house scripts were used to obtain 
read counts for protein kinases.  Read counts were summed for all isoforms of each 
kinase gene.  The raw kinase transcript read counts were then normalized with a 
calculation of reads per kilobase of exon model per million mapped reads (RPKM)130.  
The value of “N” (total number of mappable reads) in the RPKM formula was defined as 
the total number of aligned reads minus the duplicate reads.  Additionally, the mean 
isoform length for each gene was used in the RPKM calculations.   
 
Western blotting 
Proteins from cell lysates were separated by SDS-PAGE chromatography, 
transferred to nitrocellulose membranes, and probed with the indicated primary 
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antibodies.  Antibodies recognizing pAKT (S473), pAKT (T308), pAXL (Y702), AXL, c-
MYC, DDR1, EGFR, pERK1/2 (T202/Y204), pHER3 (Y1197), MAX, pMEK1/2 
(S217/S221), MEK1/2, MKP3, pP70S6K (T389), pPDGFRβ (Y751), pPDGFRβ (Y1009), 
pPDGFRβ (Y857), PDGFRβ, pRAF (S338), pRSK1 (T359/S363), pVEGFR2 (Y1175), 
VEGFR2 were obtained from Cell Signaling Technology.  Antibodies for c-MYC (C-
terminal), Cyclin A2, Cyclin B1, Cyclin D1, ERK2, MEK2 and RAF were obtained from 
Santa Cruz Biotechnology.  The antibody recognizing BIM was obtained from Chemicon.  
The antibody recognizing p-c-MYC (S62) was obtained from Abcam.  Secondary HRP-
anti-rabbit, HRP-anti-mouse and HRP-anti-goat secondary antibodies were from 
Jackson Immunoresearch Laboratories, GE Healthcare and Santa Cruz Biotechnology, 
respectively.  Western blots were visualized by incubation with SuperSignal West Pico 
Chemiluminescent Substrate (Thermo Scientific). 
 
RTK arrays 
Cells were harvested in RTK array lysis buffer containing 20 mM Tris-HCl (pH 
8.0), 1% NP-40, 10% glycerol, 137 mM NaCl, 2 mM EDTA, 1X EDTA-free protease 
inhibitor cocktail (Roche), and 1% each of phosphatase inhibitor cocktails 1 and 2 
(Sigma).  After incubating on ice for 20 minutes, cell debris was pelleted at 4°C.  Lysates 
(500 µg protein) were applied to R&D Systems Proteome Profiler™ Human Phospho-
RTK antibody arrays.  Washing and secondary antibody steps were performed 
according to the manufacturer’s instructions.  RTK arrays were visualized by 
SuperSignal West Pico Chemiluminescent Substrate (Thermo Scientific). 
 
Generation of c-MYC(T58A) SUM159 and T2-C3Tag Cells 
Phoenix cells were transfected with either pMSCV MYC(T58A) puro (Addgene 
Plasmid 18773) or empty vector pMSCV.  Retrovirus-containing media was filtered 48h 
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post-infection after addition of polybrene (6 µg/ml), and placed on SUM159 and T2 cells 
for 36h.  After an additional 4d in fresh media, cells were selected in either 3 µg/ml 
(SUM159) or 6 µg/ml puromycin (T2-C3Tag) for one week.  Selected cell populations 
were used in subsequent experiments. 
 
ChIP-PCR 
Cells were fixed for 10 min in 1% formaldehyde, sonicated (VCX130 
Ultrasonicator), and immunoprecipitated with 5 µg anti-c-MYC and protein A dynabeads 
(Invitrogen).  Crosslinking was reversed by overnight incubation at 65°C, and DNA was 
purified with the MinElute PCR purification kit (QIAGEN).  ChIP assay was quantified by 
real-time PCR using Absolute Blue SYBR green PCR mix (Thermoscientific).  Fold 
enrichment was determined by the 2^-ΔCT method using the following PCR primers 
designed to amplify 75-100 bp fragments from genomic DNA: forward 5’-
GGCTTTGAGACGTGAAAAGGA-3’ and reverse 5’-GGTCATCCAGCACAGATTGGA-3’; 
forward 5’-TGGGCCTTGGTTTGTCCTT-3’ and reverse 5’-
CATGGAGGAGATGGAAAGATCCT-3’. 
 
Inhibitor-conjugated bead preparation 
Inhibitor beads were prepared via carbodiimide coupling of appropriately 
derivatized kinase inhibitors to ECH Sepharose 4B (Lapatinib, Bisindoylmaleimide-X, 
SB203580, Dasatinib, PP58 and VI16832) or EAH Sepharose 4B (Purvalanol B) (GE 
Healthcare).  Briefly, ECH-Sepharose and EAH-Sepharose beads were washed with 
50% DMF/EtOH followed by incubation with kinase inhibitors in 50% DMF/EtOH and 
0.1M EDC (Sigma) at pH 5-6 overnight at 4°C in the dark.  Following coupling, excess 
remaining groups were blocked with 0.1M N-ethyl-N’-(3-dimethylaminopropyl) 
carbodiimide hydrochloride (EDC) in 50% DMF/EtOH 1M ethanolamine (ECH-
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Sepharose) or 20 mM HAc in 50% DMF/EtOH (EAH-Sepharose).  Subsequently, beads 
were washed with 50% DMF/EtOH and alternating washes of 0.1 M Tris-HCl (pH 8.3) 
and 0.1 M acetate (pH 4.0) buffers, each containing 0.5 M NaCl.  Inhibitor beads were 
stored in 20% ethanol at 4°C in the dark.  See Figure 2.1 for structures of inhibitor-bead 
conjugates. 
 
MIB statistical analysis 
Data obtained from the MALDI TOF/TOF was processed with the ProteinPilot 
software to identify proteins from database searches and quantify changes in binding of 
kinases to MIBs using the Paragon Algorithm.  The search results are further processed 
by the Pro Group Algorithm to determine the smallest justifiable set of detectable 
proteins and relative protein levels.  We performed three replicates of SILAC labeled 
SUM159 cells treated with AZD6244 (2 ‘heavy’, 1 ‘light’) or DMSO to assess the 
reproducibility of MIB kinase affinity capture.  A total of 113 unique kinases are identified.  
For each kinase, we computed the pool protein ratio and p-value across the three 
replicates as follows.  Let yij denote the log2 protein ratio for kinase i, i=1, …,113 in 
replicate j,  j=1,2,3.  The pool protein ratio for kinase i is defined as 2^yi, where 
yi=(
3
j=1yij)/3.  To avoid directional conflict, we convert the two-sided p-value reported in 
ProteinPilot to one-sided p-value and denote it as pij.  We apply Stouffer’s z-score 
method to combine the p-values.  Let zij=
-1(1-pij), where  is the standard Gaussian 
cumulative distribution function.  Define the combined Z-score as zi=(
3
j=1zij)/√3.  The 
combined two-sided p-value for kinase i is given as pi = 2(1-(|zi|)).  We also assessed 
the overlap/concordance between the kinases ranked by p-values for any two pairs of 
replicates.  For each replicate, we identified kinases which exhibit statistically significant 
changes in expression based on Benjamini-Hochberg adjusted p-values at FDR of 0.05 
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to account for multiple comparisons.  24, 13 and 10 kinases are identified to be 
statistically significant for replicate 1, 2 and 3, respectively.  24 kinases are identified to 
be statistically significant in the pooled p-values. 
 
Cell viability assays using siRNA knockdown of protein kinases 
siGENOME pooled siRNAs for the genes of interest were obtained from 
Dharmacon, Thermo Scientific.  RNAi assays were performed in either 96- or 384-well 
clear bottom plates.  Prior to the assay, transfection conditions were optimized for 
SUM159 or MDA-MB-231 cells using Dharmafect transfection reagent and siRNAs for 
GAPDH (negative control), and UBB (lethality control).  A 40 µl mixture of Dharmafect 
and siRNA was plated into each well by a multi-channel pipette and then followed by 
adding 160 µl cell suspension using a microplate dispenser.  The final assay volume was 
200 µl with a dose of 25 nM siRNA.  Drug or vehicle solvent was added to the cell 
suspension before plating the cells.  The assay was performed in triplicate and each 
plate had quadruple positive (UBB) and negative (GAPDH) controls.  After 96h 
incubation at 37°C with 5% CO2, the number of viable cells in each well was determined 
by a luminescence viability assay with a Pherastar microplate reader.  The % activity 
was calculated against the averages of positive and negative controls (% activity = 100 x 
(1 - [raw value - σp]/[σn - σp], where σp and σn are averages of raw values for the 
positive and negative controls, respectively.  Each median in triplicate was used as a 
representative of % activity in the figures.  Two-to-three independent experiments were 
performed with each cell line and siRNA.   
 
Phosphoproteomics analysis of MIBs 
Phosphopeptides were enriched from MIB elution digests using TiO2 beads as 
previously described131.  Tryptic peptides were separated by reverse phase nano-HPLC 
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using a nanoAquity UPLC system (Waters Inc).  Peptides were first trapped in a 2 cm 
trapping column (75 μm ID, C18 beads of 2.5µm particle size, 200 Å pore size) and then 
separated on a self-packed 25 cm column (75 μm ID, C18 beads of 2.5µm particle size, 
100 Å pore size) at room temperature.  The identity and phosphorylation status of the 
eluted peptides was determined with a Velos-Orbitrap mass spectrometer (Thermo-
Scientific).  Specifically, following a FT full scan, MS2 spectral data were acquired by 
one of three dissociative methods on the 9 most intense ions from the full scan, taking 
into account dynamic exclusions.  For ion dissociation, collision induced dissociation 
(CID), high energy collision induced dissociation (HCD) or a CID/HCD toggle was 
employed.  The polysiloxane lock mass of 445.120030 was used throughout.  All raw 
data were converted to mzXML format and then searched using Sequest on a Sorcerer 
2.0 platform (Sage N Research, Milpitas, CA).  The search was semi-tryptic on the 
human IPI database (10/3/2010) appended with reversed sequences as decoys.  
Dynamic modifications for phosphorylated serines, threonines, and tyrosines were used, 
as well as a static modification for carbamidomethylated cysteines.  Another search was 
also performed with the SpectraST algorithm provided in the Transproteomic Pipeline 
(TPP) version 4.4.1 using the NIST human ion trap database (1/14/2010).  Results from 
the Sequest and SpectraST searches were analyzed using TPP's PeptideProphet and 
then combined using IProphet132.  SILAC ratios were calculated with the XPRESS 
algorithm within TPP.  XPRESS parameters were heavy arginines' with a mass 
difference of 10 and heavy lysines' with a mass difference of 6.  Protein identifications 
were output by TPP's ProteinProphet. 
 
Immunofluorescence and TUNEL assays 
Tumors were snap frozen, cryosectioned at 6 µm and fixed in 4% 
paraformaldehyde for 15 min.  Sections mounted on glass slides were incubated 
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overnight with PDGFRβ rabbit antibody (Cell Signaling #3169) at 1:1000 dilution.  
Secondary antibody was Alexa 555 goat-anti rabbit.  Protocol provided by Cell Signaling 
for staining of cryosections was followed.  TUNEL assays were performed using the In 
Situ Death Detection Kit per manufacturers protocol (Roche, #12156792). 
 
Chapter IV 
Cell culture 
MDA-MB-231 were grown in DMEM/F12 supplemented with 10% FBS.  SUM159 
and SUM229 cells were grown in DMEM/F12 supplemented with 5% FBS, 1 µg/ml 
hydrocortisone and 5 µg/ml insulin.  BT474, SKBR3, and HCC1806 cells were grown in 
RPMI with 10% FBS.  Media containing kinase inhibitors was replaced daily. 
 
Multiplexed inhibitor bead affinity chromatography 
Performed as in Chapter III. 
 
MS analysis 
Performed as in Chapter III. 
 
Human breast tissue procurement 
All human breast tissue was obtained from the Tissue Procurement Facility in 
compliance with the laws and institutional guidelines as approved by the UNC IRB 
committee.   
 
Compounds and reagents 
Lapatinib, dasatinib and erlotinib were purchased from LC Labs.  BEZ235, 
BGJ398, MK2206 and XL184 were purchased from Selleck.  Foretinib and AZD6244 
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were synthesized according to the procedures described in two patent applications 
(WO2005030140A2, WO2007002157A2).  Compounds for MIBs were 
acquired/synthesized as in Chapter III.  siGENOME siRNAs for the genes of interest and 
Dharmafect transfection reagent were obtained from Dharmacon, Thermo Scientific.   
 
RNA sequencing, alignment and transcript expression analysis 
Performed as in Chapter III. 
 
Western blotting 
Proteins from cell lysates were separated by SDS-PAGE chromatography, 
transferred to nitrocellulose membranes, and probed with the indicated primary 
antibodies.  Antibodies recognizing pAKT (S473), pAKT (T308), DDR1, EGFR, pEGFR 
(Y1045), pEGFR (Y1068), pEGFR (Y1173), EpCAM, pERK1/2 (T202/Y204), HER2, KIT, 
pMET (S1234/S1235) and vimentin were obtained from Cell Signaling Technology.  
Antibodies for cyclin B1, ERK2 and FGFR2 were obtained from Santa Cruz 
Biotechnology, and the E-cadherin antibody was from Upstate.  Secondary HRP-anti-
rabbit, HRP-anti-mouse and HRP-anti-goat secondary antibodies were from Jackson 
Immunoresearch Laboratories, GE Healthcare and Santa Cruz Biotechnology, 
respectively.  Western blots were visualized by incubation with SuperSignal West Pico 
Chemiluminescent Substrate (Thermo Scientific). 
 
Cell viability assays  
Cells were plated in 96-well plates at low density (200-2000 cells per well) and 
grown in the presence of drug for 72h, with daily replacement of drug and media.  For 
luminescence viability assays, 50 µL of Cell Titer-Glo (Promega) was added to each well 
containing 100 µL of media.  Plates were incubated at room temperature for 10 minutes 
35 
 
and luminescence was measured by a Pherastar microplate reader.  For cell counting 
assays, nuclei were stained with Hoechst 33342 (Invitrogen, 1:4000) and counted with a 
Cellomics ArrayScan VTI (Thermo).  
 
Chapter V 
Compounds 
Selumetinib, sorafenib, BEZ235, and compounds for MIBs were acquired or synthesized 
as previously described100.  Trametinib for in vitro experiments was purchased from 
Selleck.  Conjugation of inhibitors to beads was performed by carbodiimide coupling to 
ECH Sepharose 4B (bisindoylmaleimide-X, SB203580, lapatinib, dasatinib, VI16832 and 
PP58) or EAH Sepharose 4B (purvalanol B) (GE Healthcare). 
 
The MEK inhibitors trametinib and selumetinib gave similar kinome reprogramming 
responses in preclinical models as shown previously1. Similarly, in cultured cell systems 
trametinib, selumetinib and U0126 were similar in regulating MEK1 and MEK2, induction 
of kinome reprogramming and inhibition of proliferation.  This is consistent with the 
different MEK inhibitors binding to a common allosteric regulatory site and having the 
same mechanism of action.  
 
Cell culture 
SUM159, SUM229, MDA231, T11, WHIM12 and Hs578t cell lines were grown in 
DMEM/F12 supplemented with 5% FBS, 1% penicillin/streptomycin, 1 µg/ml 
hydrocortisone and 5 µg/ml insulin.  HCC1806, MDA-MB-468, 2225, and HCC1937, 
were grown in RPMI with 10% FBS and 1% penicillin/streptomycin.  All cells were 
incubated at 37C with 5% CO2.  Media and drug was replaced daily for experiments 
longer than 24h.   
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Western blotting 
Cell lysates were subjected to SDS-PAGE chromatography and transferred to 
nitrocellulose membranes before western blotting with primary antibodies.  Antibodies 
against pAKT (T308), pAKT (S473), pAXL (Y702), AXL, BIM,  c-MYC, DDR1, DDR2, 
EpCAM, pERK1/2 (T202/Y204), pFOXO3(T32), HER2, HER3, KIT, pMEK1/2 
(S217/S221), pPKC(pan), pPDGFRβ (Y751), PDGFRβ, pRAF(S289), pRAF (S338), 
SNAIL, pSRC (Y416), VEGFR2 and Vimentin were obtained from Cell Signaling 
Technology.  Antibodies for Cyclin A, Cyclin B1, Cyclin D1, ERK2 and FGFR2 were 
obtained from Santa Cruz Biotechnology.  Antibodies against Aurora A, BRD4 and E-
Cadherin were from Upstate, Active Motif and BD Transduction Laboratories, 
respectively.  Secondary HRP-anti-rabbit and HRP-anti-mouse were obtained from 
Jackson Immunoresearch Laboratories.  SuperSignal West Pico Chemiluminescent 
Substrate (Thermo Scientific) was used to visualize blots. 
 
qRT-PCR 
Performed as in Chapter III. 
 
MIB/MS analysis 
Performed as in Chapter III. 
 
Cell viability assays using siRNA knockdown of protein kinases 
Performed as in Chapter III. 
 
RTK arrays 
Performed as in Chapter III. 
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Kinome clustering and visualization 
Two-way complete linkage unsupervised hierarchical clustering was utilized to visualize 
the activity pattern of the top 100 most variable kinases by median absolute deviation 
across the tumors. The analysis was carried out on logarithm transformed kinase quant 
ratios in R (http://www.r-project.org/). 
 
Proliferation assays 
For short-term growth assays, 200-2000 cells were plated per well in 96-well plates and 
allowed to adhere and equilibrate overnight.  Drug was added the following morning and 
replaced daily. After 72 hrs of drug treatment, cells were stained with Hoechst 33342 
(Invitrogen, 1:4000) for 30 minutes at 37C, washed with PBS and counted with a 
Cellomics ArrayScan VTI (Thermo) using Cellomics Scan software v7.6.2.1 (Thermo). 
For colony formation assays, cells were plated in 6-well dishes (200-1000 cells per well) 
and incubated overnight before continuous drug treatment for 30 days, with drug and 
media replaced twice weekly.  At the end of treatment, cells were rinsed with PBS and 
fixed with chilled methanol for 10 min at -20C.  Methanol was removed by aspiration 
and cells were stained with 0.5% crystal violet in 20% methanol for 20 min at room 
temperature, washed with distilled water, and scanned.  For quantitative analysis, crystal 
violet was solubilized from stained cells with 30% acetic acid and analyzed at λ=590 for 
relative quantitation of staining.  Error bars represent standard deviation. 
 
Cell sorting 
SUM229 cells were trypsinized and resuspended in Hank’s Balanced Salt Solution 
containing 2% fetal bovine serum (HF media). For analytical flow cytometry, cells were 
fixed with 3% paraformaldehyde.  Cells were stained for 30 minutes at 4°C with the 
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fluorescently-labeled primary antibodies EpCAM-FITC (Stem Cell Technologies) and 
CD49f-PE-Cy5 (BD Biosciences), washed twice with HF media and filtered with a 0.2 µm 
filter. Fixed cells were analyzed using a Beckman-Coulter CyAn Cytometer, and live 
cells were sorted using a Sony iCyt Reflection Cytometer.  Sorting was analyzed with 
FlowJo v7.6.5 software. 
 
In vivo tumorigenesis experiments 
The UNC Institutional Animal Care and Use Committee approved all mouse protocols.  
Drug treatment was administered through chow, provided ad libitum upon discovery of a 
palpable tumor.  Tumors were harvested by snap-freezing in liquid nitrogen and stored 
at -80C. 
 
Human breast tissue procurement 
Human breast tissue was acquired from the Tissue Procurement Facility in full 
compliance with the laws and institutional guidelines as approved by the UNC IRB 
committee.  Gene expression analysis was used to define subtypes of clinical 
specimens. 
 
Window trial 
Eligible women included those with stage I-IV newly diagnosed and previously untreated 
triple negative breast cancer that was accessible for biopsy and surgery; stage I-IIIc 
subjects could not be candidates for therapeutic neoadjuvant treatment. Triple negative 
status was based upon the clinical assays and defined by ASCO/CAP criteria including 
estrogen receptor (ER) and progesterone receptor (PR) <1% staining by 
immunohistochemistry (IHC) and HER2-negative by IHC or fluorescence in situ 
hybridization. Study subjects provided written informed consent that included details of 
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the nontherapeutic nature of the trial, and the study was approved by the UNC Office of 
Human Research Ethics. After enrollment, study subjects underwent core biopsy of the 
breast tumor, and then received trametinib for the 7 consecutive days prior to the 
scheduled surgery date. The last dose of trametinib was taken < 24 hours before 
surgery.  At surgery a post trametinib tumor specimen was reserved for research. 
Patients were monitored for toxicity during and up to several weeks after treatment, until 
any evidence of toxicity had resolved. The dosing schedule of trametinib was determined 
by the surgery date; delays in standard therapy for trial purposes were not permitted. 
Given the nontherapeutic nature of the trial, the dose was deliberately set low at 1.5 mg 
orally daily under fasting conditions; this dose was increased per protocol to 2 mg daily 
after interim analysis of pharmacodynamic endpoints in the pre- and post-treatment 
tumor samples from, and toxicity assessment of, the first 3 patients enrolled.  
 
Biopsy and surgical specimens were immediately placed into liquid nitrogen. Both pre- 
and post- trametinib tumor tissue was analyzed for baseline kinome profile and for the 
dynamic effects of MEK inhibition on the whole kinome.  Frozen tissue intrinsic subtyping 
was performed by gene expression profiling using Agilent DNA microarrays and the 
PAM50 algorithm133; claudin-low subtyping used a centroid-based predictor8.   
  
Statistical analysis of patient tumor peptides 
Kinome response to trametinib in patient tumors was determined by MIB/MS using 
quantitative iTRAQ labeling on a MALDI TOF-TOF 5800 (ABSCIEX).  A breast cancer 
cell line mix consisting of HER2amp (BT474 and SKBR3), luminal (MCF7), basal-like 
(HCC1806, SUM229, MDA-MB-468 and SUM149) and claudin-low (SUM159, MDA-MB-
231, HS578T and WHIM12) cell lines was used as a reference sample. Five untreated 
snap-frozen basal-like TNBC patient tumors obtained from UNC Tissue Procurement 
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Facility and two patient (Pt.1. and Pt. 2) 7d-tramatinib treated tumors from the window 
trial were used in the analysis.  Endogenous protein kinases from tumors and the breast 
cancer cell mix were isolated using MIBs and iTRAQ-labeled for quantitative comparison 
of peptides. MEK1 and MEK2 peptide abundance from each tumor was quantitatively 
determined as an iTRAQ ratio of tumor/breast cancer cell line mix.  Differences in MIB-
binding of MEK1 and MEK2 relative to control between trametinib treated tumors and the 
five untreated tumors was analyzed using non-parametric Mann Whitney tests to 
compare the peptide abundance between control and MEKi treated patients for MEK1 
and MEK2. False discovery rate (FDR) control was used to adjust for multiple testings. 
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Figure 2.1 Structures of bead-conjugated kinase inhibitors.  A) Bead-inhibitor 
conjugates are shown for specific and pan-kinase inhibitors used for MIB-based isolation 
of protein kinases. 
 
 
 
III.   DYNAMIC REPROGRAMMING OF THE KINOME IN RESPONSE TO TARGETED 
MEK INHIBITION IN CLAUDIN-LOW TRIPLE NEGATIVE BREAST CANCER 
 
Introduction 
Kinase-targeted cancer therapies can fail when tumor cells circumvent the action 
of a single agent, facilitating therapeutic resistance.  Acquired or selected mutations can 
decrease affinity for kinase inhibitors, but resistance also develops through alternate 
routes of kinase pathway activation.  For example, RTK upregulation has been observed 
following targeted inhibition of selective kinases; this kinome reprogramming 
circumvents inhibition of proto-oncogenic kinases54,63,67,134.  Alternatively, genomic loss 
of PTPN12 phosphatase expression similarly causes activation of multiple tyrosine 
kinases135.  Thus, dynamic and system-wide changes in multiple kinases can occur in 
tumor cells following pharmacological or progressive genetic perturbations.  An 
understanding of these kinome responses and the mechanisms by which they occur will 
be crucial for determining how to abrogate therapeutic resistance.  With over 130 kinase-
specific inhibitors currently in Phase 1-3 clinical trials, developing combination therapies 
relevant for molecularly-defined cancer subtypes is a highly tractable goal.  However, 
rational design of kinase inhibitor combinations requires an overall knowledge of kinome 
activity and response, not just a simple measure of an inhibitor’s effect on one or two 
kinase pathway components.  Currently, there is no optimal discovery mechanism to 
define the entire kinome and its dynamic activity.  Such a technique could globally 
assess tumor kinome response to small molecule inhibitors and suggest more effective 
combination therapies.
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To meet this challenge, we developed a chemical proteomics approach using 
multiplexed kinase inhibitor beads and mass spectrometry (MIB/MS) to define and 
quantitate the activity and drug responsiveness of a significant percentage (50-60%) of 
the expressed kinome.  We applied this technique to triple negative breast cancer cell 
lines, pre-clinical tumor models and human tumors.  Analysis of patient TNBC showed 
activated RAF-MEK1/2-ERK1/2 signaling, supporting MEK as a target in TNBC.  
Pharmacologic MEK inhibition in TNBC cell lines and genetically engineered mouse 
model (GEMM) tumors resulted in rapid kinome reprogramming through the induced 
expression and activation of multiple tyrosine and serine/threonine kinases that 
bypassed the initial MEK-ERK inhibition.  Alterations in virtually every tyrosine and 
serine/threonine kinase family were observed.  The mechanism of this kinome 
reprogramming involved the proteolytic degradation of c-MYC following MEK1 and 
MEK2 inhibition which resulted in increased expression and activity of RTKs.  MIB/MS 
analysis showed that reprogrammed kinase activation overcame MEK2 (but not MEK1) 
inhibition leading to therapeutic resistance.  The MEK inhibitor kinome response 
signature allowed us to predict and test the efficacy of a novel small molecule kinase 
inhibitor combination.  The combination synergistically inhibited TNBC cell line 
proliferation and caused apoptosis and tumor regression in the C3Tag GEMM of basal-
like/claudin-low TNBC. 
 
Results 
Kinome profiling of TNBC 
 We built upon previous chemical proteomic work to develop methods for isolating 
the endogenous kinome from whole cell lysates and interrogating kinase expression and 
activity dynamics through mass spectrometry (MIB/MS)122.  Ten different kinase inhibitor 
beads were generated and tested for the distribution and number of kinases captured 
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(Figure 3.1A,B).  As expected, some kinase inhibitor beads were fairly specific for 
kinases captured, such as lapatinib (with high binding of EGFR) and bisindoylmaleimide-
X (which bound mostly GSK3α/β and PKC isoforms), while others, like purvalanol B, 
PP58, and VI16832, were promiscuous.  Multiplexing beads within a single column 
enhanced the number of kinases captured and provided the greatest assessment of 
kinome expression and activity.  Kinase capture with inhibitor beads is reproducible and 
is a function of  the affinity of kinases for the immobilized inhibitors, kinase expression, 
and the activation state of the kinase116.  Using MIB/MS, we have observed that different 
cell types and model systems exhibit partially overlapping but unique signatures of 
kinome expression and activity100,136.  Across all cell line and tumor models tested, 
approximately 360 protein kinases and 24 metabolic kinases were observed above a 
cutoff of 90% confidence. 
 TNBC clinical trials of single kinase inhibitors have largely failed, consistent with 
drug-induced activation of alternative survival signaling pathways.  Figure 3.2A outlines 
our strategy to interrogate kinome dynamics with the goal of defining endpoints leading 
to rational design of combination therapies.  RNA-seq defined the transcript-level 
expressed kinome and affinity capture of endogenous kinases followed by quantitative 
mass spectrometry measured kinome activity profiles in tumors and cells.  The 
proteomic assessment was used to define the kinome response to targeted inhibition of 
kinases.  RNAi tested growth and survival functions of the kinases activated in response 
to inhibitors, and the cumulative results were used to rationally predict kinase inhibitor 
combinations to test in models of TNBC. 
The kinome transcript expression profile of a patient’s claudin-low breast tumor 
and two claudin-low TNBC lines, SUM159 and MDA-MB-231, was determined by RNA-
seq.  Greater than 400 of the 518 human protein kinases were expressed in the claudin-
low human TNBC tumor and cell lines (Figure 3.2B).  Approximately 10% of the kinases 
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expressed in the claudin-low patient tumor were unique compared to the claudin-low cell 
lines, undoubtedly due to the tumor’s complex cellular composition.  The majority of 
expressed kinases are common between tumor and claudin-low cell lines, suggesting 
that interrogating the cellular kinome response to inhibitors will be relevant to patient 
tumors. 
Profiling kinase activity in tumors and cell lines was carried out using multiplexed 
inhibitor beads (MIBs), consisting of a subset of the immobilized, linker adapted, kinase 
inhibitors (bisindoylmaleimide-X, SB203580, dasatinib, lapatinib, VI16832, purvalanol B, 
and PP58)123.  Acute changes in activation-dependent binding were demonstrated by the 
increased binding of MAPK pathway kinases in EGF-stimulated cells and the increased 
retention of tyrosine kinases from cells treated with the tyrosine phosphatase inhibitor 
pervanadate (Figures 3.2C,D).  Our data showed that MIBs capture the majority of the 
expressed kinome estimated by RNA-seq and detect altered kinome activity profiles in 
response to stimulus or clinical kinase inhibitors. 
Using MIBs and mass spectrometry, we have cumulatively sequence identified 
more than 320 kinases from cell lines and tumors.  MIB/MS profiling of an invasive 
ductal carcinoma breast tumor and two claudin-low cell lines identified approximately 50-
60% of the expressed kinome (Figures 3.2E-G).  Kinases from all major kinome 
subfamilies were captured, with a large percentage representing the untargeted 
kinome24.  iTRAQ labeling of digested MIB elutions allowed quantitative profiling of 
kinases in patient invasive ductal carcinoma compared to adjacent uninvolved mammary 
tissue (Figure 3.3A).  Of the kinases detected, there was a general increase in MIB 
binding of tumor kinases, suggesting escalated kinome activity in the tumor compared to 
uninvolved mammary tissue.  For example, the RAF-MEK-ERK pathway is increased in 
MIB binding in the tumor relative to control tissue, consistent with ERK activity being a 
driver for TNBC proliferation.  Immunoblots confirmed the activation of RAF-MEK-ERK 
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signaling in the patient invasive ductal carcinoma (Figure 3.3B).  RTK arrays further 
revealed tyrosine phosphorylated RTKs in two human tumors, which showed 
phosphorylation of EGFR, HER2, PDGFRβ, CSF1R, RON and EPHB2 (Figure 3.3C).  
Although our data pointed to the potential importance of tyrosine phosphorylated EGFR 
and PDGFRβ in patient TNBC, clinical trials targeting these RTKs have largely 
failed137,138.  The failure of single agent RTK inhibitors in TNBC is consistent with drug-
induced activation of multiple kinases or compensatory tumor kinome responses.  Since 
many expressed RTKs drive ERK activation, we profiled claudin-low breast cancer cells 
after MEK inhibition (e.g. AZD6244 currently in clinical trials), to determine if dynamic 
kinome reprogramming occurs.  Our goal was to define kinome alterations that would 
suggest a more effective, rationally designed combination therapy. 
 
Reprogramming the kinome in response to MEK inhibition 
MEK inhibitors AZD6244 or U0126 inhibited growth of SUM159 (Figure 3.4A) and 
MDA-MB-231 cells (Figure 3.4B).  ERK remained inhibited after 4h of MEK inhibitor 
treatment, while MEK phosphorylation was enhanced (Figure 3.4C).  Inhibitor treatment 
for 24h resulted in reactivation of ERK, demonstrating both lines overcame the initial 
MEK inhibition (Figures 3.4C,D).  Phosphoproteomic analysis revealed loss of ERK-
mediated feedback regulation of both BRAF and MEK1 (Table 3.1).  Reduced 
phosphorylation of negative feedback sites on BRAF and MEK1 indicate escape from 
the suppressive feedback regulation on the ERK pathway139.  Analysis of MIB isolated 
protein kinases identified 52 peptides with decreased and 59 peptides with increased 
phosphorylation, while the phosphorylation status of 365 phosphopeptides was 
unchanged after MEK inhibition.  The majority of these phosphorylation sites were 
serine, threonine and proline-directed serine/threonine sites, but phosphotyrosine 
changes were also included, suggesting a broad change in kinome activity in response 
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to AZD6244. 
We next used MIB/MS to profile the SUM159 kinome response after exposure to 
AZD6244 (Figure 3.4E).  MEK inhibition resulted in time-dependent MIB binding 
changes for more than 140 kinases, including cell cycle regulatory kinases, MAPK 
pathway kinases, RTKs, cytosolic TKs and other serine/threonine kinases.  Figure 3.4F 
highlights the MIB binding dynamics for MAPK component kinases during the time 
course of MEK inhibitor response in SUM159 cells.  At 4h of AZD6244 treatment both 
MEK1 and MEK2 are inhibited, as measured by loss of MIB binding.  However, while 
MEK1 binding remains largely inhibited, MEK2 binding to MIBs increases at 12h of 
treatment and by 24h was similar to control cells, indicating a return of MEK2 activity.  In 
parallel to restored MEK2 binding to MIBs, RAF1 and ERK1 binding to MIBs increased 
over the time course of AZD6244 treatment, correlating with activation of these kinases.  
We used RNAi for each kinase in the MAPK pathway to determine if knockdown had a 
differential growth affect in response to MEK inhibition (Figure 3.4G).  RNAi knockdown 
showed that loss of MEK2 and ERK1 inhibited SUM159 cell growth in the presence of 
MEK inhibitor, whereas MEK1 knockdown did not enhance growth inhibition.  Taken 
together, these data indicate that MEK2 and ERK1 can escape from inhibition by 
AZD6244, suggesting a critical role for MEK2/ERK1 in SUM159 growth and survival 
during AZD6244 treatment. 
Figures 3.5A and B present a 21-kinase signature defining a reprogrammed 
kinome in response to MEK inhibitors.  This signature shows a loss of cyclin-dependent 
kinases, consistent with growth inhibition, and increased ERK binding to MIBs indicating 
escape from MEK inhibition.  RTKs including AXL, DDR1 and PDGFRβ, cytosolic 
tyrosine kinases FAK2 and JAK1, and the serine kinase ACVR1 all showed increased 
MIB binding.  While MDA-MB-231 cells have a somewhat less robust kinome response 
to AZD6244, they displayed a significant kinome reprogramming that included a strong 
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increase in PDGFRβ binding to MIBs (data not shown). 
RTK arrays confirm the increased tyrosine phosphorylation of multiple RTKs, 
including PDGFRβ and AXL in response to MEK inhibition (Figure 3.5C).  In SUM159 
cells AZD6244 also significantly increased tyrosine phosphorylation of VEGFR2 and 
RET.  The AZD6244 response of SUM159 cells is dose-dependent (Figure 3.5D), as 
PDGFRβ and VEGFR2 show increased RTK phosphorylation and expression with 
increasing AZD6244.  These results demonstrate that a significant number of kinases 
were induced in response to MEK inhibition.  Relevant to the changes in the kinome to 
MEK inhibition, Table 3.2 lists the 40 highest expressed kinase transcripts of a patient 
claudin-low tumor.  Of these 40 kinases, 14 (24%) were dynamically regulated in 
SUM159 and/or MDA-MB-231 cells in response to AZD6244, suggesting patient tumors 
could have a similar kinome reprogramming in response to targeted kinase inhibition. 
 
MEK inhibition deregulates transcription, expression and activation of RTKs 
Figure 3.6A defines the time course of kinome reprogramming to AZD6244 in 
SUM159 cells.  MEK and ERK were rapidly inhibited, allowing accumulation of MKP3, 
the MAPK phosphatase that inactivates ERK140.  Increased MKP3 expression combined 
with AZD6244 to strongly suppress ERK activity, but MKP3 protein was lost as MAPK 
pathway activity returned.  Over time, VEGFR2, PDGFRβ and DDR1 expression was 
increased with AZD6244 treatment, as was the phosphorylation of HER3 and AXL.  
qRT-PCR analysis of SUM159 cells treated with AZD6244 demonstrated elevated RNA 
levels for several of these RTKs (Figure 3.6B), including DDR1/2, PDGFRβ, VEGFR2 
(SUM159 only) and HER2/3.  Analysis of cytokine RNA expression showed EGF, Gas6, 
PDGFB and PDGFD induction, indicating the establishment of autocrine/paracrine loops 
for RTK activation (Figure 3.6C).  RTK arrays further showed a time dependent increase 
in tyrosine phosphorylation of PDGFRβ, VEGFR2 and HER2/3 (DDR1/2 are not on the 
49 
 
array) (Figure 3.6D).  PDGFRβ whose RNA and protein expression was induced in 
response to AZD6244, was phosphorylated at tyrosines 751, 857 and 1009; sites 
required for PDGFRβ activation and recruitment of PI3K and PLC (Figure 3.6E). 
After 30d of continuous exposure to AZD6244, SUM159 cells have become 
significantly resistant to MEK inhibitor-induced growth arrest (Figure 3.6F).  Expression 
of cyclins A2 and B1 have recovered, consistent with increased proliferation (Figure 
3.6G).  The AZD6244-resistant cells (SUM159-R; grown continuously in 5 µM AZD6244) 
continue to have a reprogrammed kinome where PDGFRβ and VEGFR2 exhibited both 
increased expression and tyrosine phosphorylation, and AXL showed increased tyrosine 
phosphorylation (Figures 3.6D,H).  Activation of these RTKs was accompanied by 
increases in phosphorylated AKT, RAF, p70 S6 kinase, MEK, ERK and RSK1, showing 
that the cells overcame MEK inhibition by RTK activation of the ERK, AKT and mTOR 
pathways (Figure 3.6H). 
 These findings indicate that targeted MEK inhibition significantly alters the activity 
of multiple kinases.  It was therefore important to determine if the changes in kinase 
activity were specific for MEK inhibition or a function of growth arrest.  BEZ235 is a dual 
PI3K/mTOR inhibitor that strongly inhibits SUM159 cell growth (Figure 3.7A).  BEZ235 
inhibited p70 S6 kinase activity consistent with mTOR inhibition but had no effect on the 
ERK pathway (Figure 3.7B).  We compared the SUM159 kinome responses to BEZ235 
and AZD6244 to determine if kinome reprogramming was target-specific or a function of 
growth arrest.  Whereas AZD6244 induced PDGFRβ, VEGFR2 and AXL 
phosphorylation, BEZ235 treatment did not change the RTK phosphorylation profile 
except for increased phosphorylation of INSR, IGF1R and AXL (Figure 3.7C).  MIB/MS 
confirmed that AZD6244 altered the kinome differently from BEZ235, indicating that 
drug-induced kinome reprogramming is target-specific (Figure 3.7D). 
 
50 
 
MEK-ERK inhibition induces c-MYC degradation leading to RTK reprogramming 
ERK phosphorylates the transcription factor c-MYC at Ser62 and stabilizes c-
MYC protein by preventing its proteasomal degradation141.  Treatment of both SUM159 
and MDA-MB-231 cells with AZD6244 caused rapid loss of c-MYC protein and mRNA 
(Figures 3.8A,B).  This AZD6244-mediated repression of c-MYC protein and transcript, 
along with reduced phosphorylation of c-MYC at Ser62, resulted in decreased MYC-
MAX heterodimerization that is required for c-MYC transcriptional regulation (Figure 
3.8C)142,143.  Despite partial recovery of MEK-ERK activation after 24-72h, total c-MYC 
expression remained repressed in the continued presence of AZD6244. 
c-MYC binds the promoter of human PDGFRβ to repress PDGFRβ 
expression144.  To define the role of c-MYC loss in the AZD6244 reprogramming 
response, we applied RNAi to knockdown expression of c-MYC; the effect was 
analogous to the reprogrammed RTK and cytokine response seen with AZD6244 
treatment (Figures 3.8D-F).  Similar to the AZD6244 response, knockdown of c-MYC 
induced expression of PDGFRβ, VEGFR2 and PDGFB, and increased tyrosine 
phosphorylation of PDGFRβ, VEGFR2, HER3 and AXL.  RNAi knockdown of ERK1/2 
confirmed that ERK inhibition was the primary signal inducing loss of c-MYC mRNA 
expression in the AZD6244 reprogramming of the kinome.  Dual ERK1/2 knockdown 
resulted in reduced c-MYC and increased PDGFRβ expression (Figure 3.8G).  Thus, 
reprogramming of RTKs in response to AZD6244 occurs by loss of ERK-mediated 
stabilization of c-MYC and the subsequent transcriptional derepression of RTKs and 
cytokines that are negatively regulated by c-MYC.  BEZ235 inhibition of mTOR and PI3K 
inhibited cell growth but did not change ERK activity, c-MYC expression or RTK 
reprogramming, confirming the specificity of MEK-ERK in controlling c-MYC levels (data 
not shown). 
Proteasomal degradation of c-MYC lacking Ser62 phosphorylation triggers 
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AZD6244-induced kinome reprogramming.  Expression of a non-degradable c-
MYC(T58A) mutant in SUM159 cells significantly blocked AZD6244-mediated induction 
of PDGFRβ, DDR1 and VEGFR2 (Figures 3.8H,I).  GSK3β promotes c-MYC 
degradation, and inhibition of GSK3β stabilized c-MYC protein to repress the induction of 
PDGFRβ (data not shown).  Similarly, treatment of SUM159 or SUM159-R cells with the 
proteasome inhibitor bortezomib prevented AZD6244-mediated c-MYC degradation, 
blocked c-MYC mRNA repression, and inhibited the induction of PDGFRβ, DDR1 and 
VEGFR2 (Figure 3.8J, data not shown).  Washout of AZD6244 from SUM159 or 
SUM159-R cells led to increased ERK activity, stabilization of c-MYC expression and 
subsequent loss of RTK reprogramming (Figures 3.9A,B).  Thus, stabilizing c-MYC 
protein levels prevented the onset of RTK reprogramming to AZD6244 and reversed the 
reprogramming in SUM159-R cells.  Taken together, these findings show that AZD6244-
induced c-MYC proteasomal degradation is responsible for kinome reprogramming and 
RTK upregulation. 
In SUM159-R cells c-MYC protein, mRNA levels and MYC-MAX heterodimers 
have partially returned due to reactivated ERK stabilizing c-MYC (Figure 3.9C-E).  This 
correlates with SUM159-R cells having an increased growth rate compared to cells 
acutely treated with MEK inhibitor (Figure 3.6F).  The level of c-MYC protein, however, is 
insufficient to completely repress RTK expression, which remains elevated compared to 
control cells but at lower levels than cells treated with AZD6244 for 4-72h (Figures 
3.9D,F).  A 5-fold increase in AZD6244 concentration inhibited ERK activation in 
SUM159-R cells (Figure 3.9G) because the higher dose of MEK inhibitor more 
effectively prevented RTK-stimulated reactivation of MEK-ERK signaling.  As expected, 
the resulting loss of phospho-c-MYC S62 and total c-MYC protein led to a corresponding 
increase in RTK expression in SUM159-R cells.  Notably, the return of phospho-ERK in 
the continued presence of AZD6244 was insufficient to completely reverse RTK 
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reprogramming, suggesting ERK may not be fully reactivated.  This was shown by 
measuring the phosphorylation of two ERK substrates, RSK1 and c-MYC, after only 1h 
of AZD6244 washout from SUM159-R cells (Figure 3.9H).  Phosphorylation of both 
substrates and phospho-ERK was increased, demonstrating further activation of ERK 
shortly after the removal of MEK inhibitor.  Thus, the combination of persistent c-MYC 
transcriptional repression and partial MEK-ERK reactivation allows the maintenance of 
RTK reprogramming, leading to MEK inhibitor resistance. 
 
 RTK reprogramming rescues cells from AZD6244-induced growth arrest 
RNAi knockdown of PDGFRβ in SUM159 cells enhanced growth inhibition by 
AZD6244 (Figure 3.10A), indicating the induction of RTK signaling was critical for growth 
and survival of cells inhibited by AZD6244.  To test the role of additional RTKs in the 
rescue response of cells to MEK inhibition, we performed siRNA knockdown of RTKs 
found to be transcriptionally induced and/or tyrosine phosphorylated in response to 
U0126 in SUM159 (Figure 3.10B) and MDA-MB-231 cells (data not shown).  As controls 
we used siRNA to knockdown BRAF, RAF1 and ERK1/2; knockdown of each pathway 
member enhanced growth arrest observed with MEK inhibition.  Knockdown of PI3K and 
AKT produced a greater growth arrest response in SUM159 than MDA-MB-231 cells, 
consistent with mutant PI3K being a driver in SUM159 cells.  siRNA knockdown of LYN 
and EPHA2 had no effect on the growth of either cell type in the presence or absence of 
MEK inhibitor (LYN and EPHA2 show no change or loss of MIB binding in response to 
MEK inhibitor).  While knockdown of HER2 or HER3 had little effect in SUM159 and 
MDA-MB-231 cells, knockdown of AXL, DDR1, DDR2, PDGFRβ and VEGFR2 each 
resulted in a strong synthetic lethal-like effect in the presence of U0126.  Thus, loss of 
MEK-ERK signaling causes induction of multiple RTKs, each contributing to the 
subversion of MEK inhibition. 
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AZD6244 in combination with RTK inhibitors 
Our results suggested RTK inhibitors in combination with AZD6244 could block 
the growth-promoting activity of the reprogrammed kinome.  Given the repertoire of 
AZD6244-activated RTKs, we tested sorafenib and foretinib alone or in combination with 
AZD6244 for their ability to inhibit cell growth (Figures 3.10C,D).  Whereas the two RTK 
inhibitors were ineffective as single agents, both were synergistic in inhibiting cell growth 
in combination with AZD6244, with sorafenib being most effective.  Cell counting assays 
reinforced the strong synergistic growth arrest of SUM159 cells with the 
AZD6244/sorafenib combination (Figure 3.10E); RTK arrays validated that sorafenib 
inhibited tyrosine phosphorylation of multiple RTKs induced by AZD6244 (Figure 3.10F).  
The combination of AZD6244/sorafenib enhanced the inhibition of ERK1/2, decreased 
cyclin D1 levels and increased expression of the pro-apoptotic BIM protein compared to 
AZD6244 alone, indicating the cells were primed for apoptosis (Figure 3.10G). 
Sorafenib inhibits PDGFRα and β, VEGFR2 and DDR1/2, but is also an inhibitor 
of BRAF and RAF.  Therefore, we assayed the action of different RAF inhibitors in 
combination with AZD6244 to determine if the effect of sorafenib could be mimicked by 
other BRAF/RAF inhibitors (Figure 3.10H).  RAF inhibitors, but not sorafenib, in 
combination with AZD6244 actually stimulated the growth of SUM159 cells, consistent 
with the known activation of wild-type RAF signaling by both PLX4720 and SB590885.  
At 250-500 nM, only sorafenib synergistically inhibited growth of SUM159 cells in 
combination with AZD6244.  Thus, sorafenib in combination with AZD6244 inhibits 
growth of SUM159 cells more effectively than BRAF inhibitors by cotargeting induced 
RTKs. 
 SUM159-R cells that have become resistant to AZD6244 rely on RTK-driven 
reactivation of ERK for drug resistance.  If a 10-fold higher dose of AZD6244 is used, 
ERK activity can be inhibited (Figure 3.10I).  At the 5 µM of AZD6244 that was used to 
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develop SUM159-R cells, the addition of sorafenib inhibited ERK activity and cell growth 
(Figure 3.10J), confirming that AZD6244-induced activation of upstream RTKs drives 
ERK reactivation.  In SUM159-R cells the combination of low doses of AZD6244 and 
sorafenib was similarly effective as high dose AZD6244 at inhibiting ERK activation and 
cell growth (Figures 3.10I,J). 
 
Kinome reprogramming in the C3Tag TNBC GEMM 
The genetically engineered C3Tag mouse model has a gene expression 
signature similar to human TNBC.  To define AZD6244-mediated kinome reprogramming 
in vivo, we harvested tumor tissue before or after oral delivery of AZD6244.  Figure 
3.11A shows increased expression of PDGFRβ in response to AZD6244 in both the 
tumor cells and stroma of C3Tag tumors, demonstrating in vivo induction of PDGFRβ. 
Rapid degradation of c-MYC protein and induction of PDGFRβ was observed in 2d and 
7d AZD6244-treated tumors, consistent with loss of c-MYC repression of RTK 
expression (Figure 3.11B).  A C3Tag-derived breast cancer cell line (T2-C3Tag) isolated 
from the GEMM tumor responded to AZD6244 with upregulation of PDGFRβ and DDR1, 
confirming the tumor cell response to MEK inhibitor (Figure 3.11C).  Expression of non-
degradable c-MYC(T58A) in T2-C3Tag cells prevented the induction of PDGFRβ and 
DDR1, further indicating that proteasomal degradation of c-MYC is responsible for RTK 
reprogramming in C3Tag tumor cells (Figure 3.11D). 
 
Profiling kinome response to targeted combination therapies in the C3Tag mouse model 
of TNBC 
MIB/MS was then used to define the kinome response profile of C3Tag tumors 
from mice treated with AZD6244, sorafenib or the combination of AZD6244 and 
sorafenib (Figure 3.11E).  The MIB/MS signatures of tumors continuously treated with 
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AZD6244 or sorafenib share some overlap but exhibit significant differences, 
demonstrating drug selective reprogramming of the kinome.  AZD6244-treated tumors 
have upregulation of RTKs PDGFRβ, DDR2 and CSF1R, as well as a number of 
tyrosine kinases similar to the AZD6244 response in human TNBC cell lines.  
Importantly, the escape of MEK2 and ERK1 from AZD6244 inhibition was recapitulated 
in MIB/MS profiles of AZD6244-treated C3Tag tumors.  Sorafenib-treated tumors 
showed decreased MIB binding of the previously reported sorafenib targets: BRAF, 
PDGFRβ, CSF1R, DDR1, DDR2, KIT, MLTK and FRK117.  Both AZD6244- and 
sorafenib-treated tumors showed increased MIB-binding of cyclin-dependent kinases, 
indicating the tumors have circumvented the action of the single agents to reenter cell 
cycle progression.  MIB/MS profiling of tumors treated with the combination of AZD6244 
and sorafenib showed reduced MIB-binding of kinases activated by AZD6244 treatment 
(Figure 3.11F).  Sorafenib inhibited AZD6244-mediated activation of RTKs PDGFRβ, 
DDR2 and CSF1R, as well as a number of intracellular tyrosine kinases, including JAK1.  
RTK-driven activation of MEK2-ERK1 was inhibited by sorafenib in tumors and loss of 
cyclin-dependent kinase binding to MIBs was also observed, consistent with the 
combination of AZD6244 and sorafenib arresting tumor growth (Figure 3.11E). 
 
AZD6244 plus sorafenib causes tumor regression 
After only 2d of AZD6244 or sorafenib treatment, the expression of VEGFR2 and 
PDFGRβ was increased along with increased phosphorylation of RAF at Ser338, 
demonstrating RAF activation (Figure 3.12A).  The combination of AZD6244 and 
sorafenib reduced VEGFR2 and PDGFRβ expression, suppressed RAF activation and 
synergistically inhibited reactivated ERK.  Figure 3.12B shows the combination of 
AZD6244 and sorafenib blocked ERK activation and induction of PDGFRβ in the T2-
C3Tag cell line.  Cyclin B1 levels are also reduced by the combination therapy, and a 
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strong growth arrest was observed in cells cotreated with AZD6244 and sorafenib, 
indicating that AZD6244 sensitizes cells to sorafenib treatment (Figure 3.12C). 
Our findings showed that the combination of AZD6244 and sorafenib was 
significantly more effective in inhibiting ERK activation in 2d treated C3Tag mice and the 
C3Tag tumor cell line.  Therefore, C3Tag mice were allowed to develop tumors and then 
treated for 21d with AZD6244 and/or sorafenib (Figures 3.12D,E).  Sorafenib treatment 
alone had no effect on tumor progression, whereas 30% of the AZD6244-treated mice 
showed some tumor regression.  In contrast, 77% of mice treated with AZD6244 and 
sorafenib had tumor regression, demonstrating a significantly greater effect of the 
combination therapy versus AZD6244 alone.  TUNEL assays of the tumors showed that 
the combination of AZD6244 and sorafenib induced a strong apoptotic response in only 
2d of treatment, in stark contrast with single drug treatment (Figure 3.12F). 
 
Discussion 
We describe a novel approach to study the reprogramming of protein kinase 
networks “en masse”.  Our methods allowed the isolation and analysis of protein kinases 
from cells and tumors with 50-60% of the expressed kinome assayed in a single mass 
spectrometry run.  Profiling MIB binding of kinases is a highly sensitive method to 
simultaneously monitor activation and inhibition of numerous kinases.  This profiling 
technique allows interrogation of kinases known by sequence but which have been 
understudied due to lack of biologic or phenotypic knowledge or reagent availability.  An 
example of the latter is the ability to distinguish changes in MEK1 and MEK2. 
 This technique identified a kinome response signature to the selective MEK1/2 
kinase inhibitor AZD6244.  The only defined substrates for MEK are ERK1 and 2, yet we 
observed changes in activity of kinases in every subfamily of the kinome in response to 
MEK inhibition.  Kinome assessment showed a time-dependent reprogramming that 
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involved an early loss of ERK feedback regulation of RAF and MEK, as well as 
increased MKP3 protein stability.  The increased expression of MKP3 functions to 
enhance ERK inactivation.  In contrast, the loss of RAF and MEK feedback inhibition 
would allow upstream activation of the pathway.  The time-dependent change in MIB 
binding of specific RTKs such as PDGFRβ and DDR1 was readily detected and provided 
the critical experimental observation that MEK inhibition was driving the expression and 
activation of multiple RTKs, each of which are capable of stimulating the RAF-MEK-ERK 
pathway.  Importantly, we identified c-MYC degradation as a key mechanism mediating 
kinome reprogramming; preventing proteasomal degradation of c-MYC inhibited the 
reprogramming response.  RNAi knockdown of ERK or c-MYC recapitulated the MEK 
inhibitor-induced expression and tyrosine phosphorylation of several RTKs, 
demonstrating ERK regulation of c-MYC stability is critical in controlling the expression 
and activation of specific kinases.  The fact that multiple RTKs are activated in response 
to MEK inhibition demonstrates the difficulty in using single kinase inhibitors to arrest 
tumor progression. 
 In addition to c-MYC, inhibition of AKT and mTOR also causes kinome 
reprogramming in different breast cancer subtypes67,145.  Whereas c-MYC functions as a 
repressor of PDGFRβ, DDR1/2 and VEGFR2 expression in claudin-low breast cancer, 
AKT has been shown to negatively regulate FOXO-dependent expression of HER3, 
IGF1R and INSR in several breast cancer cell lines.  Inhibition of mTOR kinase activity 
leads to AKT inhibition and subsequent RTK reprogramming145.  Differential kinome 
reprogramming is seen not simply with targeting the MEK-ERK and AKT pathways but 
with tyrosine kinase inhibitors as well.  HER3 upregulation was shown to play a major 
role in lapatinib resistance and in lung cancer MET amplification leads to gefitinib 
resistance72,146. 
Analysis of the ERK pathway in cells treated with AZD6244 showed a time-
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dependent rescue of BRAF/RAF, MEK2, ERK1 and RSK1 binding to MIBs.  We 
demonstrated that MIB binding of these kinases is a function of their activation.  The 
time course of recovery parallels that of AZD6244-induced RTK expression.  The C3Tag 
tumor shows a comparable increase in MEK2 and ERK1 binding after AZD6244 
treatment, mimicking the reprogramming response observed in SUM159 cells.  
Published work with a similar MEK inhibitor, GSK1120212, which binds to the MEK 
allosteric regulatory site (as does AZD6244) provides insight into how MEK2 escapes 
inhibition33.  MEK1 phosphorylated at the activation loop serines has a 20-fold lower 
affinity for GSK1120212 than nonphosphorylated MEK1, effectively alleviating allosteric 
site inhibition of MEK.  Because ERK activity is increasing over time, MEK1 would be 
feedback phosphorylated at its negative regulatory site Thr292, preventing MEK1 
reactivation even in the setting of RTK reprogramming; MEK2, however, lacks this 
regulatory site and selectively escapes inhibition.  This suggests a unique paradigm of 
activation of an upstream signaling pathway increasing the IC50 of an inhibitor for a 
target kinase.   
In many tumor types tyrosine kinases are molecular drivers of transformation and 
also play a major role in resistance to therapy.  Claudin-low SUM159 cells and the 
C3Tag breast cancer GEMM were remarkably similar in response to AZD6244, with 
induction and activation of PDGFRβ, VEGFR2, CSFR1, DDR1/2 and AXL.  The claudin-
low MDA-MB-231 cell line was somewhat less responsive, but still showed the induction 
of PDGFRβ, DDR1 and DDR2 and activation of AXL with AZD6244 treatment.  RNAi 
knockdown of the different RTKs indicated that each kinase contributed to the survival 
response of SUM159 and MDA-MB-231 cells.  Given the repertoire of RTKs whose 
expression and activity is induced with AZD6244 treatment, we predicted that the 
combination therapy of sorafenib and AZD6244 would “broaden” the kinase targeting 
sufficiently to produce significant therapeutic benefit.  The combination therapy 
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increased apoptosis and tumor regression significantly compared to either drug alone in 
the C3Tag TBNC GEMM. 
 We identified AZD6244-induced RTKs (and serine/threonine kinases) using a 
combination of MIB/MS and immunoblotting of cell lines and C3Tag tumors.  We created 
a signature of therapeutic resistance allowing a rational prediction of combinatorial 
therapies in claudin-low breast cancer.  This approach can be extended to human 
tumors using so-called “window trials” in which a patient is treated with a targeted agent 
prior to surgery and their tumor analyzed at excision for kinome-resistance signatures.  
Importantly, we have shown that the kinome response is unique for inhibitors targeting 
different kinases and the response of different tumor types to a common inhibitor may 
also vary.  Thus, this systems kinome approach can be applied to help define patterns of 
resistance for a variety of drugs and biopsy-accessible tumor types.
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Figure 3.1 Kinase capture of inhibitor beads.  A) Distribution of kinases captured 
using individual inhibitor beads.  Binding of atypical or metabolic kinases are 
represented in lower left corner of kinome trees.  B) Number of kinases captured using 
each inhibitor bead and a combined column of bisindoylmaleimide-X, SB203580, 
lapatinib, dasatinib, purvalanol B, PP58, and VI16832.  For each run, HuMEC lysate 
containing 5 mg of total protein was applied to the column.  
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Figure 3.2 Strategy and characterization of MIBs.  A) Experimental strategy.  B) Venn 
diagram shows number of expressed kinases defined by RNA-seq across TNBC 
samples.  C) Increased binding of EGFR signaling components following EGF 
stimulation.  SILAC labeled MDA-MB-231 cells were serum starved overnight and 
stimulated with 30 ng/ml EGF for 15 min, harvested and applied to MIBs.  A SILAC-
based quantitative comparison of MIB-bound kinases was performed.  D) Increased 
binding of tyrosine kinases to MIBs following pervanadate treatment.  SILAC labeled 
CML cells (MYL) were treated with 100 µM pervanadate for 15 min, harvested and 
kinome isolated using MIBs.  A SILAC-based comparison of MIB-bound kinases in the 
presence or absence of pervanadate was determined.  E) Venn diagram shows number 
of kinases captured and identified by MIB-based proteomics across TNBC samples.  F) 
Distribution and G) overlap of expressed and MIB-bound kinases across TNBC samples. 
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Figure 3.3 RAF-MEK-ERK pathway activation in TNBC.  A) RAF-MEK-ERK pathway 
activated in patient TNBC tumors.  Quantitative comparison of patient TNBC to matched 
uninvolved mammary tissue using MIB/MS.  The line graphs show iTRAQ determined 
quantitative changes in MIB binding as a ratio of tumor/uninvolved.  Ratio <1 denotes 
decreased MIB binding and >1 increased MIB binding of kinase in tumor versus control 
tissue.  B) Immunoblotting confirms an activated RAF-MEK-ERK pathway in TNBC cell 
lines and TNBC patient samples.  C) RTK array analysis of patient TNBC tumors reveals 
multiple Tyr phosphorylated RTKs, including EGFR and PDGFRβ. 
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Figure 3.4 Profiling MEKi response in claudin-low TNBC.  Growth inhibition of A) 
SUM159 and B) MDA-MB-231 cells in response to AZD6244 or U0126.  Triplicate 
experiments + SD.  Reactivation of MEK and ERK in the continued presence of 5 µM 
AZD6244 was shown by western blot in C) SUM159 and D) MDA-MB-231 cells.  E) 
Activation and repression of the kinome in response to 5 µM AZD6244 in SUM159 cells.  
Line graphs show iTRAQ-determined quantitative changes in MIB binding as a ratio of 
AZD6244/DMSO.  Ratio <1 denotes decreased and >1 denotes increased MIB binding 
of kinases in treated versus control cells.  F) MEK2 and ERK1 escape AZD6244 
inhibition.  MIB/MS binding profile of RAF-MEK-ERK from SUM159 cells treated with 5 
µM AZD6244 for 4, 12 and 24h or 5 µM U0126 for 24h.  G) MEK2 and ERK1 promote 
survival following MEK inhibition.  siRNA knockdown of MAPK signaling components in 
SUM159 cells shows loss of MEK2, but not MEK1, inhibits growth in the presence of 
U0126. 
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Table 3.1 MIB-based phosphoproteomics of RAF-MEK-ERK pathway.  Loss of ERK 
regulated feedback of the RAF-MEK-ERK pathway and downstream signaling.  SUM159 
cells were treated with 5 µM AZD6244 for 12h and kinome phosphorylation analyzed by 
MIB/MS. 
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Figure 3.5 Defining a signature of kinome response to MEKi in claudin-low TNBC.  
A) Kinome response signature for MEK inhibition in SUM159 cells.  Triplicate MIB/MS 
runs of SILAC-labeled SUM159 cells ± 5 µM AZD6244 or U0126 relative to DMSO.  
Error bars represent mean + SD where kinases are significant at FDR of 0.05.  B) 
Kinome map of AZD6244 response (blue: inhibited, red: induced) as determined by 
MIB/MS and RTK arrays.  C) Increased tyrosine phosphorylation of RTKs in response to 
MEK inhibition.  SUM159 and MDA-MB-231 cells were treated with 5 µM AZD6244 or 
U0126 for 24h and analyzed by RTK array.  D) Dose-dependent RTK reprogramming in 
response to AZD6244.  Dose-dependent induction of RTK expression and activity in 
24h-treated SUM159 cells was determined by western blot. 
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Table 3.2 Top 40 kinases expressed in patient claudin-low tumor.  RPKM values for 
each kinase determined by RNA-seq.  *denotes AZD6244-responsive kinase in 
SUM159/MDA-MB-231 cell profiling. 
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Figure 3.6 Characterization of CL RTK response.  A) Western blot of long-term 
AZD6244 treatment in SUM159 cells.  B) Time-dependent increase in RTK and C) 
cytokine expression in SUM159 cells after AZD6244 treatment, determined by qRT-
PCR.  D) Prolonged treatment of AZD6244 leads to stable upregulation of RTKs, as 
shown by RTK arrays.  E) Treatment with AZD6244 enhances phosphorylation of 
PDGFRβ at multiple sites, including the activation loop.  F) Increased cell growth of 
SUM159-R cells compared to SUM159 cells treated with AZD6244 for 72h determined 
by cell counts (*p-value<0.001).  G) Return of cyclin expression in SUM159-R cells 
compared to SUM159 cells treated with AZD6244, as determined by qRT-PCR.  H) 
Maintenance of RTK reprogramming in SUM159-R cells accompanied by increased 
survival signaling, as shown by western blot.  Error bars represent triplicate ± S.D. 
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Figure 3.7 Induced kinases are target-specific to MEKi.  A) SUM159 cells are growth 
inhibited by U0126 (5 µM), AZD6244 (5 µM), and BEZ235 (50 nM).  B) BEZ235 inhibits 
p70 S6 kinase activity but not ERK1/2 signaling in SUM159 cells.  C) AZD6244 and 
BEZ235 are target-specific in their reprogramming of kinome response.  BEZ235 
induces a kinase response different from AZD6244 in SUM159 cells, despite similar 
growth inhibition.  D) Treatment of SUM159 cells with BEZ235 (50 nM) induces a distinct 
kinome response compared to AZD6244 or U0126 (5 µM), as determined by MIBs/MS 
using iTRAQ.  Drug treatments are standardized to untreated SUM159 cells, and only 
kinases with statistically significant changes (pvalue<0.1) are shown.  Error bars 
represent triplicate experiments + SD.   
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Figure 3.8 Defining mechanisms of MEKi response.  Stable suppression of c-MYC A) 
protein and B) RNA after MEKi treatment.  C) Disruption of MYC-MAX complexes after 
MEKi treatment.  Knockdown of c-MYC with D) deconvolved or E) and F) pooled siRNA 
for 72h in SUM159 cells induced kinase expression and activity.  G) siRNA-mediated 
knockdown of ERK1/2 suppresses c-MYC expression, inducing PDGFRβ transcript, as 
shown by qRT-PCR.  H) Retroviral expression of c-MYC(T58A) in SUM159 cells 
suppresses RTK induction after 24h of 5 µM AZD6244, as shown by western blot and 
quantified by densitometry.  I) DDR1, PDGFRβ and VEGFR2 transcripts are reduced by 
expression of c-MYC(T58A) in the presence and absence of 5 µM AZD6244.  SUM159 
cells were treated for 24h and analyzed by qRT-PCR.  J) Stabilization of c-MYC protein 
levels by bortezomib prevents AZD6244-mediated kinome reprogramming.  SUM159 
cells were treated with AZD6244 (5 µM) or bortezomib alone or in combination for 24h.   
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Figure 3.9 Effects of drug removal or prolonged treatment on c-MYC and RTK 
reprogramming.  Removal of AZD6244 results in stabilization of c-MYC protein and 
reversal of RTK reprogramming.  AZD6244 was removed from the media of A) SUM159 
cells after 24h of treatment or B) SUM159-R cells.  C) c-MYC protein levels partially 
return in SUM159-R cells, while AZD6244-mediated RTK reprogramming is reduced but 
still maintained.  SUM159 cells were treated with AZD6244 and RTK and c-MYC levels 
compared to SUM159-R cells by western blot.  D) Increased c-MYC RNA levels in 
SUM159-R cells relative to AZD6244 treated SUM159 cells.  SUM159 cells were treated 
with DMSO or 5 µM AZD6244 for 4h and c-MYC gene expression compared to 
SUM159-R cells using qRT-PCR (*p-value<0.001).  E) Recovery of c-MYC stability and 
MYC:MAX heterodimers in SUM159-R cells.   MAX IP from SUM159 cells shows 
MYC:MAX heterodimerization is inhibited at 4h and 72h of 5 µM AZD6244 treatment, but 
not in SUM159-R cells.  The recovery of c-MYC transcript and MYC:MAX 
heterodimerization in SUM159-R correlates to the partial suppression of RTKs in 
SUM159-R cells compared to SUM159 cells acutely treated with AZD6244.  F) 
AZD6244-induced RTK expression is maintained at reduced levels in SUM159-R cells.  
qRT-PCR was used to compare gene expression in SUM159 cells treated with AZD6244 
for 24h or SUM159-R cells relative to DMSO-treated cells.  G) c-MYC stabilized by RTK-
mediated ERK activation in SUM159-R cells.  RTK reprogramming and c-MYC levels 
were determined by western blot comparing SUM159-R treated with AZD6244 for 24h.  
H) RTK-mediated reactivation of ERK is incomplete in the continued presence of 
AZD6244.  AZD6244 (5 µM) was removed from media of SUM159-R cells for 1h and 
ERK1/2 phosphorylation of c-MYC and RSK1 determined by western blot.   
Error bars represent triplicate experiments ± S.D. 
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Figure 3.10 Targeting induced RTKs.  A) RNAi knockdown of PDGFRβ enhances 
AZD6244-induced growth arrest.  PDGFRβ knockdown with 1.25 µM AZD6244 in 
SUM159 cells for 96h and cell growth assayed by Cell-Titer Glo.  B) Knockdown of 
MEKi-responsive RTKs in SUM159 cells synergizes with U0126 to inhibit proliferation, 
as determined at 96h of treatment by Cell-Titer Glo.  Cotreatment with AZD6244 and C) 
sorafenib or D) foretinib synergizes in cell growth inhibition of SUM159 cells, as 
determined by Cell-Titer Glo.  E) Cell counting of AZD6244/sorafenib treated SUM159 
cells.  F) Sorafenib inhibits AZD6244-mediated activation of RTKs, as shown by RTK 
arrays.  G) Cotreatment of SUM159 cells with AZD6244/sorafenib enhances ERK 
inhibition and promotes apoptosis.  H) AZD6244/sorafenib synergizes to inhibit SUM159 
growth better than AZD6244 and targeted RAF inhibitors PLX4720 or SB590885.  I) 
Inhibition of ERK activity in SUM159-R cells occurs after high dose MEKi or cotreatment 
of MEKi with sorafenib.  J) SUM159-R cells require MEKi-induced RTK activity for drug 
resistance, as shown by cell counting.*p-value<0.001; Triplicate experiments ± S.D. 
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Figure 3.11 Kinome reprogramming in C3Tag GEMM.  A) PDGFRβ is induced in 
C3Tag tumors after 2d AZD6244 treatment, as shown by immunofluorescence.  B) 
AZD6244 treatment of C3Tag mice for 2 and 7d causes c-MYC degradation and induced 
PDGFRβ expression, as shown by western blot.  C) Tumor-derived C3Tag cell line 
shows AZD6244-mediated c-MYC loss and RTK induction.  T2-C3Tag cells were treated 
with AZD6244 and RTK reprogramming determined by western blot.  D) Expression of c-
MYC(T58A) in T2-C3Tag cells suppresses AZD6244-mediated RTK reprogramming.  
T2-C3Tag cells stably expressing vector or human c-MYC(T58A) were treated with 
AZD6244 for 24h and analyzed by western blot.  E) MIB/MS profile of C3Tag tumors in 
response to AZD6244 for 28d, sorafenib for 26d, or combined AZD6244 and sorafenib 
for 26d show distinct kinome responses.  The line graphs show iTRAQ-determined 
quantitative changes in MIB binding as a ratio of inhibitor/untreated.  Ratio <1 denotes 
decreased MIB binding and >1 increased MIB binding of kinases in treated versus 
control tumors.  F) AZD6244 plus sorafenib inhibits AZD6244-induced kinome response 
in C3Tag tumors, as identified by MIB/MS.  Changes in MIB binding (>1.5 fold) of 
AZD6244-responsive kinases following cotreatment with sorafenib are shown in yellow. 
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Figure 3.12 AZD6244/sorafenib combination produces synergistic effects in C3Tag 
mice.  A) AZD6244 (20 mg/kg) or sorafenib (30 mg/kg) fed in chow results in ERK 
activation after 2d of treatment in C3Tag GEMM, while cotreatment with AZD6244 and 
sorafenib inhibits RTK-mediated ERK activation.  RTK reprogramming was monitored in 
tumors treated with AZD6244 and/or sorafenib relative to untreated tumors by western 
blot.  B) Sorafenib inhibits AZD6244-dependent reactivation of ERK, promoting c-MYC 
degradation and loss of cyclin B1 expression in T2-C3Tag cells.  T2-C3Tag cells were 
treated for 24h and analyzed by western blot.  C) AZD6244 and sorafenib synergize to 
inhibit cell growth in C3Tag cell line.  T2-C3Tag cells were treated with AZD6244 and 
sorafenib, alone or in combination, and cell growth determined by cell counting (*p-
value<0.001; quadruplicate experiments).  D) Cotreatment of C3Tag mice with AZD6244 
and sorafenib for 21d causes significant tumor regression compared to AZD6244 alone.  
C3Tag mice were treated with AZD6244 (20 mg/kg), sorafenib (30 mg/kg) or the 
combination of AZD6244 and sorafenib and compared to untreated tumors.  Percent 
change in tumor volume of drug treated relative to untreated is shown (* Wilcoxon p-
value=0.007).  E) Tumor volumes of C3Tag breast tumors during a 21d time course of 
AZD6244 and/or sorafenib treatment.  F) Increased apoptosis of C3Tag mouse tumors 
following cotreatment with AZD6244 and sorafenib.  Apoptosis in C3Tag tumors treated 
for 2d was determined by TUNEL staining (shown in red; DAPI is grayscale). 
 
 
IV.   INVESTIGATING RESISTANCE TO EGFR/HER2 INHIBITION IN BASAL-LIKE 
AND OTHER BREAST CANCER SUBTYPES 
 
Introduction 
 The epidermal growth factor receptor (EGFR) has recently emerged as another 
potential therapeutic target in TNBC147. Multiple groups report EGFR to be 
overexpressed in a significant proportion (40-70%) of basal-like or triple-negative breast 
cancers, and this high expression of EGFR has been linked by multivariate analysis of 
patient TNBCs to poorer prognosis for disease-free and overall survival148,149. These 
findings implicate EGFR as contributing to tumor growth and resiliency in EGFR-
expressing TNBCs. However, phase II and III clinical trials combining chemotherapeutics 
with EGFR-targeting agents (i.e. cetuximab or lapatinib) show no improvement in 
progression-free or overall survival of TNBC patients by the addition of these EGFR 
inhibitors138,150. A possible explanation for this paradox is that targeted inhibition of 
EGFR in TNBC causes cancer cells to compensate for the loss of EGFR by the 
upregulation of parallel growth signaling pathways. Indeed, multiple studies have linked 
EGFR inhibitor resistance in TNBC to the rapid induction of alternative RTKs or 
SFKs78,151.   
 We have previously shown that treating claudin-low TNBC cells with targeted 
MEKi initiates a rapid reprogramming of the kinome to drive drug resistance.  This effect 
was shown to be target-selective with distinct kinome reprogramming events occurring 
after MEK1/2 or PI3K/mTOR inhibition, suggesting that EGFR inhibition with lapatinib 
may induce a unique kinome response.  To test this, we applied our MIB/MS strategy
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towards defining how breast cancer cells respond to targeted EGFR/HER2 inhibition for 
basal-like, claudin-low, and HER2-amplified subtypes.  Interestingly, a significant 
disparity in baseline levels of activated EGFR was observed between the two TNBC 
subtypes, with basal-like cell lines having much higher phosphorylated EGFR than 
claudin-low cells.  The presence of phosphorylated EGFR in patient tumors and basal-
like cell lines validates EGFR as a target in basal-like (but not claudin-low) breast 
cancer.  However, the inability of lapatinib to strongly inhibit basal-like cancer cell growth 
and growth signaling pathways suggests that mechanisms of intrinsic and/or adaptive 
resistance protect basal-like TNBC cells from EGFR inhibition.  Inhibition of EGFR/HER2 
with lapatinib caused a robust RTK reprogramming in basal-like and HER2-amplified cell 
lines, but a minimal response in claudin-low cell lines lacking EGFR phosphorylation.  
Loss of downstream signaling after EGFR inhibition was shown to cause RTK induction 
in HCC1806 cells, with reduced activity of ERK and AKT contributing independently to 
the overall reprogramming.  EGFR inhibition was not sufficient to completely inhibit ERK 
or AKT pathway activation, possibly due to compensatory preexisting or induced RTKs, 
suggesting that combination therapies will be necessary for inhibiting cell growth.  Small 
molecule inhibitor combinations targeting EGFR and induced RTKs were tested in 
multiple basal-like cell lines, yielding synergistic growth inhibition.   
 These data define another unique instance of kinome reprogramming in breast 
cancer, highlighting the importance of considering kinome adaptation to any targeted 
kinase inhibitor.  Interestingly, while EGFR inhibition provides a distinct strategy to target 
basal-like TNBC, the downstream inhibition of ERK was the greatest contributor to the 
transcriptional component of kinome reprogramming, suggesting that any TKI causing 
ERK inhibition will similarly circumvent growth inhibition through induction of alternative 
RTKs.  The demonstrated benefit of kinase inhibitor combinations that target induced 
kinases further supports the notion that single-agent kinase inhibitor strategies will 
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ultimately fail.   
 
Results 
Defining EGFR expression and activity in TNBC 
 The failure of targeting EGFR in TNBC clinical trials, despite high EGFR 
expression and correlation with poor prognosis, led us to investigate possible causes of 
insensitivity to EGFR inhibitors in basal-like and claudin-low TNBC.  Efforts to target 
EGFR in TNBC are largely based upon gene expression analysis showing elevated 
EGFR expression, which may be independent of EGFR activity.  To address this, we first 
probed TNBC patient samples for EGFR phosphorylation to determine whether TNBCs 
exhibit activated EGFR (Figure 4.1A).  Tyrosine phosphorylation at three sites, including 
two major autophosphorylation sites (Y1068 and Y1173) was observed with varying 
intensity across seven basal-like TNBC patient tumors, suggesting that EGFR is actively 
signaling in these tumors.  To validate TNBC cell lines as models for studying EGFR 
inhibition, we blotted a panel of basal-like and claudin-low TNBC cell lines for total and 
phospho-EGFR.  While EGFR expression was fairly consistent between claudin-low and 
basal-like cell lines, phosphorylated EGFR was found exclusively in basal-like lines 
(Figure 4.1B).  This unexpected result highlights the disparity between expression and 
activity, a pitfall of gene expression analysis, and reveals subtype-specific EGFR 
signaling in TNBC.  While basal-like TNBC may benefit from EGFR inhibition, it is clear 
that claudin-low TNBC lacks EGFR activity (despite elevated EGFR expression) and is 
likely intrinsically resistant to EGFR-targeted therapies.  Differential EGFR 
phosphorylation in non-tumorigenic RMF (mesenchymal, similar to claudin-low) and 
HuMEC (epithelial, similar to basal-like) cell lines suggest that EGFR activation may 
depend largely on the differentiation state of the cell.   
 Treatment of a panel of basal-like and claudin-low cell lines with the EGFR/HER2 
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inhibitor lapatinib resulted in little to no growth inhibition, whereas HER2-amplified 
SKBR3 cells were strongly inhibited (Figure 4.1C). Treatment with an alternative EGFR 
inhibitor, erlotinib, showed a similar lack of efficacy in claudin-low and basal-like cell 
lines (data not shown).  Similarly, lapatinib treatment only partially affected ERK and 
AKT signaling in basal-like cell lines, whereas downstream signaling was strongly 
inhibited in SKBR3 cells and unaffected in claudin-low lines (Figure 4.1D).  Claudin-low 
cells were not expected to respond due to the lack of active EGFR, but the insensitivity 
of basal-like cell lines suggests that these cells are able to evade growth inhibition after 
loss of activated EGFR.   
 
MIB/MS defines kinome response to EGFR inhibition 
 In order to define possible mechanisms of resistance to EGFR inhibition, we 
applied MIB/MS to measure the kinome response to lapatinib in basal-like, claudin-low, 
and HER2+ cell lines (Figure 4.2A).  Two cell lines from each subtype were analyzed, 
yielding over 260 kinases across the six cell lines.  Though inhibition of EGFR and HER2 
was evident whenever these kinases were quantified, induction of distinct kinase 
signatures was observed in each case.  HER2+ cell lines responded robustly, with 
activation of DDR1, FRK, MYLK3, NEK9, and YES in SKBR3 cells and CDK9, CSK, 
FRK, INSR, LYN, and YES in BT474 cells (FDR cutoff at 0.05).  Though most of these 
are not known to be involved in HER2-inhibitor resistance, SRC-family kinases such as 
FRK, LYN, and YES have been shown to confer resistance in this setting, confirming the 
MIB/MS strategy as a method to define resistance mechanisms78,152.  Claudin-low cell 
lines were not expected to exhibit a kinome response, and this was the case with MDA-
MB-231 cells where no kinases were induced at an FDR of 0.05.  Interestingly, induction 
of ABL1, EPHB4, EPHA2 and KS6A1 was observed in response to lapatinib in SUM159 
cells.  This may be a result of inhibition of low-level EGFR activity or off-target effects of 
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lapatinib.  Basal-like HCC1806 cells responded robustly to EGFR inhibition, exhibiting 
activated DDR1, FGFR2, KIT, and MET after lapatinib treatment.  Induced 
expression/activity of these kinases was confirmed by western blotting of a time course 
and dose-response of lapatinib treatment in HCC1806 (Figure 4.2B,C).  The time course 
of EGFR inhibition shows an initial loss of downstream ERK signaling that returns 
coincidentally with increased RTK expression.  The RTK induction, with the exception of 
pMET, was sustained after 30 day treatment with lapatinib (HCC1806-R) and 
phosphorylated ERK neared untreated levels (Figure 4.2D).  In contrast, SUM229 cells 
were unresponsive to lapatinib treatment, with no induced RTKs and only a very 
transient loss of ERK and AKT signaling (data not shown).  However, these cells are 
known to have abundant and highly activated MET, which may be contributing to an 
intrinsic immunity to EGFR inhibition in these cells151. 
  
Mechanisms of reprogramming to EGFR inhibition 
 To determine whether kinome reprogramming to lapatinib in HCC1806 was 
occurring at the mRNA level, RNA-seq was used to define transcriptional changes 
following EGFR inhibition.  From more than 20,000 genes sequenced, 1437 genes 
exhibited a >1.5-fold change in expression, with 79 kinases significantly altered (Figure 
4.3A).  In concordance with the MIB/MS data, expression levels of DDR1, KIT, and 
FGFR2 were substantially increased by lapatinib treatment (Figure 4.3B), as well as 
other kinases not well represented by MIB/MS (including FGFR3, HER2, CIT, RIPK4).   
Expression of MET was not increased, consistent with MET induction occurring at the 
level of kinase activation rather than induced expression.  Interestingly, expression of 
MET ligand HGF was low and unresponsive to lapatinib treatment, indicating MET 
activation may occur through a ligand-independent mechanism.  While treatment of 
HCC1806 with lapatinib caused a transcriptional induction of DDR1, FGFR2, and KIT, 
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EGF treatment reduced expression of these RTKs and attenuated RTK induction by 
lapatinib (Figure 4.3C).  These data suggest that the RTK reprogramming to EGFR 
inhibition results from changes to signaling pathways downstream of EGFR affecting 
transcription factor activity.  Because lapatinib treatment prevents EGFR-mediated 
signaling through the ERK and AKT pathways, targeted MEK1/2 and AKT inhibitors were 
used to define the relative contributions of these pathways to RTK reprogramming.  
Whereas inhibition of MEK1/2 with AZD6244 caused induction of KIT, DDR1 and 
FGFR2, AKT inhibitor MK2206 strongly activated MET (Figure 4.3D).  Thus, the RTK 
reprogramming observed after EGFR inhibition likely results from loss of signaling 
through both ERK and AKT.   
 ERK and AKT act upon numerous transcription factors to affect gene 
transcription, often regulating protein levels of transcription factor substrates through 
phosphorylation.  We have previously shown that RTK reprogramming to MEK inhibition 
in claudin-low TNBC occurs through loss of negative gene regulation from the 
transcription factor c-MYC.  In an effort to define transcription factors downstream of 
ERK and AKT that are directly responsible for RTK reprogramming in HCC1806, 
proteasomal inhibition was used to determine whether stabilizing high-turnover proteins 
affects the reprogramming response to lapatinib.  Inhibition of the proteasome with 
bortezomib attenuated lapatinib induction of DDR1, FGFR2 and KIT, but did not affect 
pMET induction (Figure 4.3E).  These data are consistent with ERK acting on one or 
more transcription factors that negatively regulate DDR1, FGFR2, and KIT expression.  
To provide some insight into which transcription factors may be responsible for RTK 
induction, the RNA-seq data was analyzed for alterations in transcription factor 
expression following lapatinib treatment (Figure 4.3F).  More than 60 transcription 
factors were reduced in expression >1.5-fold due to lapatinib, with some known to be 
downstream of ERK, including c-MYC, FOSL1, ETV4 and ETV5.  The transcriptional 
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regulation of the induced RTKs is largely unknown, so these ERK-regulated transcription 
factors were tested as candidate mediators of RTK reprogramming.  Unfortunately, no 
induction of RTKs was observed when these kinases were knocked down by siRNA to 
mimic their loss following EGFR inhibition (Figure 4.3G,H).  While the loss of the 
transcription factors undoubtedly causes significant changes to cell composition and 
signaling, they do not appear to be mediating RTK induction.  The use of expression 
data may be misleading to the search for transcription factors responsible for RTK 
reprogramming, as the bortezomib data indicates protein stabilization to be a greater 
factor.  Additionally, more than one transcription factor could regulate RTK 
reprogramming, and loss of a combination of transcription factors may be necessary for 
the induced RTK expression.  
 
Targeting lapatinib-induced RTKs 
 Having defined a core set of RTKs induced by EGFR inhibition in HCC1806 cells, 
our next goal was to determine whether these RTKs were contributing to growth and 
survival during lapatinib treatment.  Knockdown of individual RTKs in the presence of 
lapatinib was used to define the contributions of each induced RTK towards preserving 
ERK phosphorylation after lapatinib treatment (Figure 4.4A).  For each RTK knockdown, 
residual ERK activity was lost to varying degrees, indicating that all induced RTKs 
provide compensatory signaling through ERK.  DDR1 knockdown caused the least ERK 
loss in the presence of lapatinib, while MET knockdown contributed the most.  MET was 
also the only kinase whose knockdown reduced ERK activity in the absence of lapatinib, 
suggesting that this is an important growth-promoting RTK in HCC1806 cells.  
Simultaneous knockdown of all induced RTKs caused the greatest suppression of 
phosphorylated ERK, to 7% of wildtype levels, indicating that the induced RTKs work in 
concert to preserve ERK signaling after EGFR inhibition.  Consistent with RTK 
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knockdown reducing ERK phosphorylation, RTK stimulation with cytokines for FGFR2, 
KIT, or MET enhanced pERK levels under serum-starved and lapatinib-treated 
conditions in HCC1806-R cells (Figure 4.4B).  These experiments confirmed that 
lapatinib-induced RTKs are important in the survival response to EGFR inhibition, 
suggesting that combination therapies targeting DDR1, FGFR2, KIT and MET would 
provide a greater benefit than EGFR inhibition alone. 
 Four TKIs with distinct targeting profiles were tested for growth inhibition in 
combination with lapatinib in HCC1806 cells.  Foretinib and cabozantinib strongly inhibit 
MET and KIT, while BGJ398 is specific for FGF receptors and dasatinib is a broader-
acting TKI that inhibits DDR1 and KIT.  Combination of lapatinib with each of these 
compounds helped to suppress residual EGFR and ERK phosphorylation in HCC1806 
cells (Figure 4.4C).  Additionally, cyclin B1 levels were lowered by the drug 
combinations, suggesting a greater arrest of the cell cycle.  Growth assays revealed that 
lapatinib combinations with foretinib, cabozantinib, BGJ398 or dasatinib synergistically 
inhibited the growth of HCC1806 cells (Figure 4.4D).  SUM229 cell growth was similarly 
inhibited with lapatinib and MET-targeted inhibitors, validating the importance of 
activated MET in the intrinsic resistance of this cell line to EGFR inhibition (data not 
shown).  The combination of lapatinib with sorafenib or imatinib, TKIs with targeting 
profiles not expected to inhibit induced RTKs, produced no additive or synergistic growth 
inhibition, consistent with induced RTKs selectively driving growth in lapatinib-treated 
HCC1806 (Figure 4.4E).   Importantly, cotreatment of lapatinib with downstream 
inhibitors to MEK (AZD6244) or AKT (MK2206) matched the benefit of targeting EGFR 
and induced RTKs, and the AZD6244/MK2206 combination provided a strong growth 
inhibition in these cells.  Taken together, these data suggest that the failure of lapatinib 
to fully inhibit signaling through ERK and AKT is one reason why HCC1806 cells are not 
strongly inhibited by EGFR inhibition.  Residual ERK and AKT can be inhibited by either 
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1) targeting induced RTKs that compensate for EGFR loss, or 2) targeting the conserved 
downstream signaling pathways directly.   
 
Discussion 
 As a whole, these studies confirm EGFR as a target in basal-like TNBC, identify 
RTKs induced by EGFR inhibition, and define those RTKs contributing to growth/survival 
after EGFR inhibitor treatment.  An important distinction between TNBC subtypes is 
made by the discovery of activated EGFR only in basal-like TNBC, despite similar 
expression levels of EGFR and associated cytokines.  The mechanism(s) behind this 
disparity in EGFR activity remain unclear, however it is known that expression of E-
cadherin and increased cell-cell interaction, hallmarks of the epithelial phenotype, can 
potentiate activation of EGFR153.  E-cadherin expression has also been linked to gefitinib 
sensitivity in lung cancer, suggesting that E-cadherin may serve as a biomarker for 
EGFR activity and susceptibility to EGFR-targeted therapies154.  Conversely, EMT and 
loss of E-cadherin expression is proposed to be a mechanism of resistance to EGFR-
targeted therapies in lung cancer155,156.  In light of these studies, the striking dichotomy of 
EGFR activity suggests the need to stratify patient populations when developing EGFR-
targeted therapies in the context of triple-negative breast cancer.  Even with careful 
selection of patients harboring basal-like TNBC, EGFR-inhibitor resistance through EMT, 
kinome reprogramming, or intrinsic resistance by pre-existing RTK activity are likely to 
occur.  Thus, it is extremely important to understand how basal-like TNBC cells respond 
to EGFR-targeted therapies in order to anticipate and prevent the onset of resistance. 
 We have previously defined a signature of kinome reprogramming to MEKi in 
claudin-low TNBC, with induced expression/activity of PDGFRβ, VEGFR2, DDR1, DDR2 
and AXL.  Interestingly, the basal-like HCC1806 cell line responds to EGFR inhibitors 
(through loss of MEK/ERK signaling) with KIT, FGFR2 and DDR1 induction, suggesting 
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that basal-like TNBC may exhibit a distinct kinome response to MEKi.  Though MEKi and 
EGFR inhibitors target very different kinases, both result is loss of signaling through 
ERK1/2, leading to the RTK reprogramming response.  Any other inhibitors leading to 
loss of ERK activity would therefore be expected to produce a similar reprogramming 
response in this context, and likewise, direct or indirect inhibition of AKT would similarly 
cause activation of MET in these cells.  These results impart a global connotation to 
kinome reprogramming because most therapeutic strategies aim to inhibit growth 
signaling through the ERK and/or AKT pathways.   
 The data presented here suggest that targeting either inhibitor-induced RTKs or 
downstream signaling helps to suppress cell proliferation after EGFR inhibitor treatment.  
However, without direct inhibition of ERK and/or AKT, there is a very high likelihood that 
cancer cells will be able to easily surmount targeted inhibition of RTKs through activation 
of alternative RTKs.  The pre-existence of activated MET, as in SUM229 cells, or other 
RTKs appears to be sufficient to make basal-like TNBC cells completely unresponsive to 
lapatinib treatment, regardless of baseline EGFR activity.  Thus, the high specificity of 
lapatinib (or other EGFR/HER2 inhibitors) may actually hinder its efficacy for treating 
TNBC and broader-acting TKIs may preclude some of the RTK redundancy and 
reprogramming in TNBC cells.  In any case, it will be difficult to comprehensively define 
pre-existing or induced RTK signaling for individual patients, complicating the rational 
design of combination therapies using TKIs.  In contrast, we know that targeting only 
downstream kinases such as ERK or AKT directly leads to kinome reprogramming and 
potentiation of upstream signaling.  Therefore is seems likely that targeting multiple 
nodes of growth signaling pathways, as well as inhibitor-induced kinases, will be the best 
strategy for sustained growth inhibition.   
 Taken together, these data highlight the resiliency of the kinome against targeted 
TKIs and reinforce the prevalence of kinome reprogramming as a mechanism of 
84 
 
resistance to kinase inhibitors.  Further investigations into subtype-specific kinome 
reprogramming and alternative strategies to surmount kinome resiliency will help to 
clarify better therapeutic strategies for TNBC treatment.  
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Figure 4.1 Characterization of pEGFR in TNBC. A) Phosphorylated EGFR is observed 
in TNBC patient tumor samples.  B) Basal-like cell lines (shown in blue) exhibit much 
higher phosphorylated EGFR compared to claudin-low cell lines (shown in red).  C) 
Basal-like and claudin-low cell lines are not growth-inhibited by treatment with lapatinib, 
whereas HER2-amplified SKBR3 cells are strongly inhibited.  D) Inhibition of EGFR does 
not necessarily lead to loss of downstream signaling through ERK or AKT. 
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Figure 4.2 MIB/MS defines kinome response to EGFR inhibition.  A) EGFR/HER2 
inhibition induces distinct kinome reprogramming events in basal-like, HER2+ and 
claudin-low cell lines.  Triplicate MIBs/MS experiments were used to define the 24h 
lapatinib-responsive kinases in two cell lines from each subtype.  B) The timecourse of 
EGFR inhibition and RTK response in HCC1806 cells was defined by western blot.  C) 
Lapatinib-induced RTKs in HCC1806 are largely dose-responsive, as shown by western 
blot.  D) Lapatinib-resistant HCC806 cells exhibit sustained RTK response after 30 day 
lapatinib treatment. 
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Figure 4.3 Investigating mechanisms of kinome reprogramming in HCC1806.  A) 
Summary of genes transcriptionally altered by lapatinib treatment in HCC1806 cells.  B) 
Transcriptional changes for kinases in HCC1806 cells after lapatinib treatment.  Two 
replicate RNA-seq experiments were performed.  Lines represent 1.5-fold change in 
expression between lapatinib and DMSO.  C) qRT-PCR of responsive RTKs with 
lapatinib and/or EGF treatment in HCC1806 cells.  D) Western blot of HCC1806 cells 
treated with inhibitors targeting EGFR and downstream signaling pathways.  E) Western 
blots showing effect of proteasomal inhibition on RTK induction.  F) Transcriptional 
changes for transcription factors in HCC1806 cells after lapatinib treatment.  Two 
replicate RNA-seq experiments were performed.  Lines represent 1.5-fold change in 
expression between lapatinib and DMSO.  G) qRT-PCR testing effects of c-MYC 
knockdown on RTK expression.  H) Western blot testing effects of transcription factor 
knockdown on RTK expression. 
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Figure 4.4 Targeting lapatinib-induced RTKs in HCC1806.  A) Western blot of 
HCC1806 cells with 72h RNAi towards induced RTKs with or without lapatinib.  Relative 
phosphorylation of ERK1/2 is quantified by densitometry.  B) HCC1806-R cells were 
treated with cytokines for induced RTKs under serum-starved and lapatinib-treated 
conditions.  C) Western blotting of TKI combinations with lapatinib reveals inhibition of 
residual ERK and arrest to the cell cycle in HCC1806 cells.  D) Combination therapies 
synergistically inhibit HCC1806 cell growth, as shown by cell counting.  E) Combinations 
with TKIs not targeting induced RTKs do not provide a benefit to growth inhibition, while 
cotargeting downstream MEK or AKT produces strong growth inhibition.  Relative cell 
growth was assayed by Cell-Titer Glo.  
 
 
V.   TRIPLE-NEGATIVE BREAST CANCER EXHIBITS SUBTYPE-SPECIFIC KINOME 
REPROGRAMMING TO TARGETED MEK INHIBITION 
 
Introduction 
Triple negative breast cancer is clinically treated as a single disease; however, 
genomic studies have shown that TNBC consists of at least two discrete molecular 
subtypes, basal-like and claudin-low8,157.  Differences in incidence, prognosis and 
response to therapy between these subtypes highlight the heterogeneity of TNBC.  BL 
breast cancer represents the majority of TNBC (70-80%), exhibits high tumor cell 
proliferation and poor clinical outcome, and lacks approved molecularly targeted 
therapies.  Though CL tumors comprise the minority of TNBC, CL breast cancer has 
generated great interest because of its correlation with tumor initiating cell features, EMT 
signature and association with metastasis and drug resistance10.  Despite elevated 
MEK-ERK gene signatures in both BL and CL patient tumors, targeting the MEK-ERK 
pathway with single-agent MEK1/2 inhibitors (MEKi) has shown limited success in 
clinical trials for TNBC.  Previous studies have shown that CL TNBC cell lines develop 
resistance to MEK inhibitors through acquired dependency on PI3K/mTOR signaling 
and/or activation of RTKs, suggesting that similar mechanisms of resistance may be at 
play in BL TNBCs51,100.  Our goal was to define the response of the kinome to targeted 
MEK inhibition in both BL and CL breast cancers and design strategies to prevent 
resistance to MEKi therapies that can be applied globally to all TNBC subtypes.   
MIB/MS kinome profiling of BL and CL cell lines and mouse tumors using 
chemical proteomics showed that each subtype reprograms to MEKi with a distinct 
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response signature facilitating resistance.  These distinct kinome response signatures, 
including activation of numerous RTKs, were further observed in TNBC patients treated 
with MEKi in a “window trial” assessing molecular tumor response.  Prolonged treatment 
of a BL/CL heterogeneic cell line or the C3Tag TNBC GEMM with MEKi resulted in the 
selection of CL reprogrammed tumors, illustrating the differential sensitivity of BL and CL 
TNBC to MEK inhibition.  Combination therapies targeting MEKi-induced RTKs delayed 
the onset of MEK inhibitor resistance, but the diversity and accumulation of the activated 
kinome response ultimately overcame the dual agents, leading to eventual resistance.  
Induced gene expression of RTKs in response to MEKi represents an essential 
component of kinome reprogramming driving resistance in both BL and CL tumors.  
Therefore, we targeted the transcriptional activation of the kinome signatures using 
epigenetic inhibitors against the “epigenetic reader” BRD4.  Inhibition of BRD4 with the 
small molecule inhibitor JQ1 blocked MEKi-mediated kinome reprogramming in both 
TNBC subtypes, prevented reactivation of MEK-ERK and caused sustained growth 
arrest.  Combination of MEKi and JQ1 abolished the MEKi-mediated selection of CL 
cells in the dual-population BL/CL SUM229 cell line, suggesting that the novel 
combination of MEK and BRD4 inhibitors may be an effective approach for TNBC 
treatment.   
 
Results 
Differential kinome reprogramming in response to MEK inhibition defines TNBC 
subtypes 
Active RAF-MEK-ERK signaling was detected in both CL and BL patient tumors, 
supporting MEK1/2 as a target in both TNBC subtypes (Figure 5.1A).  To determine the 
kinome response to MEKi in both BL and CL TNBC, kinome profiling of BL cell line 
HCC1806 and CL cell line SUM159 was carried out using MIB/MS (Figure 5.1B).  
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Treatment of TNBC cell lines with the MEK inhibitor GSK1120212 (GSK212) for 24h 
resulted in increased MIB-binding of distinct cohorts of TKs and RTKs in BL (FGFR2, 
IGF1R, DDR1, KIT) and CL (PDGFRβ, AXL, DDR1) cells.  Similarly, MIB/MS analysis of 
MEKi-treated tumors from a BL (2225; p53 null) tumorgraft mouse model showed 
increased MIB-binding of FGFR2 and FRK, while induction of PDGFRα/β, CSF1R and 
DDR2 was observed in MEKi-treated CL (T-11; p53 null) mouse tumors (Figure 5.1C).  
Induction of these distinct RTKs in response to MEKi treatment was further detected at 
both the protein and RNA level in multiple BL (HCC1806, SUM149, MDA468 and 
SUM229) and CL (SUM159, MDA231, WHIM12 and HS578T) cell lines, supporting 
MEKi-mediated RTK reprogramming as a global response in both subtypes, albeit with 
distinct subtype-specific signatures of RTK induction (Figure 5.1D-H).  Western blotting 
for nduced RTKs in 2225 and T-11 tumors and tumor-derived cell lines further confirmed 
the distinct RTK responses in tumor cells (Figure 5.1F,G).  Increased tyrosine 
phosphorylation of FGFR2, DDR1 and KIT after GSK212 treatment was observed in 
HCC1806 by RTK arrays, suggesting that MEKi-induced kinases in BL models are also 
activated (Figure 5.1I).  Furthermore, continuous treatment of either BL HCC1806 or CL 
MDA231 cells with GSK212 resulted in stable upregulation of RTKs and reactivation of 
MEK-ERK signaling, consistent with induced RTKs supporting proliferation through ERK 
reactivation (Figure 5.1J).   
Having defined distinct kinome reprogramming in BL  and CL models for TNBC, 
we tested whether the unique RTK responses required distinct combination therapies by 
cotreating BL or CL cells with MEKi in combination with FGFR inhibitor BGJ398 (to 
target BL response) or PDGFR, DDR and VEGFR2 inhibitor sorafenib (to target CL 
response).  Synergistic growth inhibition was observed only when BL or CL cells were 
cotreated with MEKi and the inhibitor targeting induced RTKs for that particular subtype 
(Figure 5.1K,L).  These data show that the distinct BL and CL reprogramming responses 
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will require separate inhibitor combinations for effective growth inhibition.   
We next evaluated the MEKi kinome response of TNBC patient tumors in a 
“window trial”, in which patients received GSK212 for 7 days prior to surgical resection of 
the tumor.  MIB/MS kinome analysis comparing a GSK212-treated patient tumor relative 
to a pre-treatment core biopsy showed decreased MIB binding of MEK1 but not MEK2, 
and increased binding of RTKs DDR1 and IGF1-R, similar to our defined BL kinome 
response signatures in preclinical models (Figure 5.2A).  Comparing pre-treatment 
biopsies to treated tumors, we observed an induction of BL MEKi-responsive RTKs 
FGFR2, KIT and DDR1 in 3 of 4 BL patients at both protein and transcript levels (Figure 
5.2B,C).  Partial inhibition of ERK and increased SRC and AKT activity were also 
detected in tumors post-GSK212 treatment from patients 3 and 4, consistent with 
induced RTKs driving downstream signaling pathways.  Due to sample limitations, the 
singular CL tumor obtained from patient 2 was suitable only for gene expression 
analysis, but this was sufficient to confirm our predicted CL-MEKi signature with induced 
gene expression of PDGFRβ, VEGFR2, CSF1R and DDR2.  Interestingly, patient 8 did 
not show induction of RTKs in response to MEKi treatment, however, evaluation of gene 
expression of FGFR2, KIT and DDR1 showed strikingly elevated expression of these 
RTKs, suggesting that the tumor was predisposed to an RTK-reprogrammed state 
(Figure 5.2D).   
Consistent with the MEKi response in our mouse models (Figure 5.2E), MIB/MS 
analysis showed inhibition of MEK1 but not MEK2 in all of the post MEKi-treated patient 
tumors analyzed by MIB-MS.  This suggested that the dose of GSK212 administered 
was ineffective at maintaining MEK2 inhibition, particularly in the context of MEKi-
induced RTK activation (Figure 5.2F,G).  Overall, both BL and CL patient tumors 
exhibited our predicted MEKi kinome reprogramming signatures identified from cell line 
and mouse models.  Elucidation of distinct kinome responses to MEKi in BL and CL 
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patient tumors validates the importance of kinome reprogramming in the clinic and 
highlights the need to understand this mechanism of resistance when treating patients 
with targeted kinase inhibitors. 
 
MEKi treatment selects for reprogrammed CL cells from heterogeneous cell line 
 Assessment of kinome reprogramming in BL and CL TNBC after MEKi treatment 
revealed that each molecular subtype exhibits a distinct inhibitor-induced RTK signature.  
Histological studies have shown that TNBC tumors have cell populations expressing 
epithelial (BL) and mesenchymal (CL) markers, supporting the presence of BL and CL 
subtypes within tumors158.  Clinically, CL tumors represent only 10% of all breast 
cancers and 20-30% of TNBC, however, claudin-low characteristics are significantly 
enriched after chemotherapy, consistent with intratumoral heterogeneity10.  Our goal was 
to define the role of differential kinome reprogramming in response to MEKi in 
heterogeneic TNBC models to determine whether CL cells are enriched by MEKi.  
Several TNBC BL cell lines, including SUM229, are known to have subpopulations of CL 
cells, providing a valuable heterogeneic BL/CL model system to evaluate subtype-
specific inhibitor responses.  Parental SUM229 cells were FACS-sorted into distinct BL 
(EpCAM+/CD49f+) and CL (EpCAM-/CD49f-) subpopulations (Figure 5.3A) and kinome 
profiles of each subpopulation analyzed by MIB/MS (Figure 5.3B).  Consistent with 
previously defined BL kinome signatures, the SUM229(+) show elevated DDR1, FRK, 
LYN and SRC relative to the SUM229(-), whereas, SUM229(-) have strong AXL and 
PKCα activity characteristic of CL cells8,159.  We evaluated the response of each FACS-
sorted population to MEKi using MIB/MS and found that SUM229(+) cells reprogrammed 
with induction of FGFR2 and DDR1, while SUM229(-) cells showed increased MIB-
binding of PDGFRβ and DDR1 (Figure 5.3C).  Subtype-specific RTK responses 
following MEKi were further observed in the sorted populations at both the protein and 
94 
 
RNA level, with elevated DDR1 common to both populations (Figure 5.3D,E).  
Importantly, return of ERK activity was detected predominantly in the SUM229(-) cells 
after MEKi treatment, consistent with RTK reprogramming in the CL population  being 
better able to reactivate MEK-ERK signaling.  The distinct kinome responses and ERK 
reactivation between sorted populations contributes to differential MEKi sensitivity, 
where SUM229(-) cells are 94-fold less sensitive to MEKi than SUM229(+) cells (Figure 
5.4A).  We next sought to define whether subtype-specific kinome reprogramming in CL 
cells provides a survival advantage following MEKi treatment in the parental population 
containing both BL and CL cells.  Following confirmation that both BL (FGFR2 and 
DDR1) and CL (PDGFRβ and AXL) RTK responses occur simultaneously in parental 
SUM229 cells (Figure 5.4B), we treated SUM229 parental cells with MEKi over 28 days 
and monitored the proportion of SUM229(+) and SUM229(-) populations.  The CL 
subpopulation was enriched from 1% to 51.9% after 28 days of MEKi, illustrating the 
selective advantage of CL reprogramming in response to prolonged MEK inhibition 
(Figure 5.4C).  SUM229 cells after 28 days of MEKi treatment (SUM229-R) were shown 
to have CL characteristics analogous to sorted SUM229(-), with expression of PDGFRβ, 
AXL and EMT marker vimentin along with loss of BL markers DDR1, EpCAM and E-
cadherin (Figure 5.4D).  Removal of MEKi from SUM229-R cells reduced RTK 
expression, confirming that MEKi-enriched SUM229(-) cells were reprogrammed (Figure 
5.4E).  Taken together, sustained MEKi treatment of a BL/CL heterogeneic cell line 
model selects for CL subpopulations that display RTK reprogramming and reactivation of 
the MEK-ERK pathway.  
 
Enrichment of tumors with CL characteristics in response to targeted kinase inhibition in 
C3Tag TNBC GEMM 
The C3Tag GEMM has been shown to share genetic similarities with patient 
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TNBC basal-like tumors, providing an in vivo BL model to study tumor responses to 
targeted therapies160.  Previous studies have demonstrated that single agent MEK 
inhibitor therapies provide minimal to no effect on C3Tag tumor growth, where tumors 
rapidly become resistant to MEKi100.  Intriguingly, although C3Tag tumors cluster tightly 
with BL TNBC, a rapid induction of the CL MEKi-mediated kinome signature was 
observed following MEKi treatment, consistent with C3Tag tumors being heterogeneic 
for both BL and CL TNBC subtypes (Figure 5.5A).  To investigate mechanisms of MEKi 
resistance in C3Tag tumors, we stably treated six tumor-bearing mice with the MEK 
inhibitor AZD6244 and defined kinome responses using MIB/MS.  Following continuous 
MEKi treatment, tumors T1-T3 gradually increased in tumor volume, whereas tumors T4-
T6 were very aggressive with exponential tumor growth (5.5B).  Analysis of kinome-wide 
changes across the six tumors revealed two distinct groups based on MEKi response, 
with T1-T3 and T4-T6 clustering independently (Figure 5.5C).  Consistent with the rapid 
tumor growth following MEK inhibition, T4-T6 showed increased MIB-binding of cell 
cycle dependent kinases.  Interestingly, comparison of TKs across the six treated tumors 
revealed increased MIB-binding of the predicted BL MEKi-signature (FRK, DDR1 and 
KIT) in T3, whereas tumors T4-T6 showed activation of the CL MEKi-signature kinases 
(PDGFRα, PDGFRβ and DDR2) (Figure 5.5D).  
 Thus it appears that the tumor response to MEKi can entail both BL and/or CL 
kinome reprogramming.  Enrichment of tumors with CL characteristics following MEKi 
treatment was further confirmed by blot, where T4-T6 showed elevated PDGFRβ, DDR2 
and CL marker vimentin, as well as loss of BL markers KIT, DDR1 and EpCAM (Figure 
5.5E).  A dramatic induction of cyclin D1, the regulatory component of the cyclin D1-
CDK4 complex and a marker of the CL subtype, was also observed consistent with rapid 
tumor growth and elevated MIB binding of CDK4.  These MEKi-resistant C3Tag tumors 
display striking similarities to CL T-11 tumors in kinase expression and signaling (Figure 
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5.5F).  Overall, these data suggest that CL and BL cells within a heterogeneic in vivo 
model of TNBC reprogram independently to MEKi treatment, and that the robust 
reprogramming of CL cells contributes to the enrichment of CL tumors following 
sustained MEKi treatment.   
 
The diversity of kinome reprogramming promotes escape from MEKi/sorafenib 
combination therapies 
The activation of numerous RTKs in the C3Tag tumors following MEKi prompted 
us to investigate the combination of MEKi with sorafenib.  Previous studies in our lab 
have shown that the combination of MEKi and sorafenib caused tumor regression and 
apoptosis in a 21-day tumor regression model.  Consistent with this observation, 
inhibition of MEKi-mediated PDGFRβ and induction of apoptotic marker BIM was 
detected in C3Tag tumors following 7-day cotreatment with MEKi and sorafenib (Figure 
5.6A).  Overall survival was improved in C3Tag mice treated with the combination of 
MEKi and sorafenib relative to single agents, though the effect was limited by the 
development of resistance (Figure 5.6B).  Despite an initial tumor regression (tumor 1), 
the original tumor often returned with a rapid growth rate, along with the development of 
fast-growing secondary tumors having CL characteristics that were detected 30-40 days 
post inhibitor treatment (Figure 5.6C-E).  Profiling of tyrosine phosphorylation in 
MEKi/sorafenib resistant tumors using RTK arrays confirmed sustained PDGFRβ 
inhibition, though persistent tyrosine phosphorylation of sorafenib targets PDGFRα and 
VEGFR3 were detected, indicating these RTKs evaded inhibition (Figure 5.6F).  
Tyrosine phosphorylation of non-sorafenib targets RON, FGFR4, MUSK and AXL were 
also detected in the tumors, demonstrating the diversity of RTK activity in the rapidly 
growing resistant tumors.  Activation of numerous downstream kinases, including 
PI3K/mTOR, PKC and the RAF-MEK-ERK pathway further revealed that the tumors had 
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(re)activated alternative survival signaling to evade the initial MEK-ERK inhibition (Figure 
5.6G).   
To define kinases promoting resistance to the dual agent therapy, we performed 
a synthetic lethality screen of the kinome with the combination of MEKi/sorafenib or 
single agents alone in CL MDA231 cells.  Knockdown of MEKi-responsive kinases not 
targeted by sorafenib, including AXL, EGFR, FGFR4, MUSK and RON, as well as 
downstream signaling kinases AKT, PKC and RAF all enhanced growth inhibition 
relative to MEKi alone (Figure 5.6H).  Knockdown of known sorafenib targets DDR1/2 in 
the combination therapy displayed enhanced growth inhibition consistent with the MEKi-
induced expression and activation of DDR1/2 overcoming the sorafenib inhibition.  
Combining the EGFR inhibitor lapatinib with both MEKi and sorafenib also enhanced 
growth inhibition in MDA231 cells, indicating the sorafenib-insensitive EGFR contributes 
to the kinome reprogramming to promote MEKi/sorafenib resistance (Figure 5.6I).  
Taken together, cotreatment of the C3Tag mice with MEKi/sorafenib resulted in an initial 
therapeutic benefit that was ultimately overcome through escape of RTKs and 
subsequent activation of multiple kinase signaling pathways.  Although sorafenib is a 
broad acting tyrosine kinase inhibitor, the diversity of MEKi/sorafenib kinome 
reprogramming in C3Tag tumors allowed tumors to exploit sorafenib-insensitive kinases 
to facilitate dual-agent resistance, demonstrating a substantial challenge in applying 
effective and stable kinase inhibitor combinations.  These data suggest that GSK212 
combinations with alternative TKIs would similarly lack the breadth of RTK inhibition to 
prevent MEK/ERK pathway reactivation (Figure 5.7), and indicate that other strategies to 
prevent RTK reprogramming may be necessary for sustained growth inhibition. 
 
Targeted BRD4 inhibition blocks kinome reprogramming in BL and CL TNBC cells  
Combination therapies directly targeting MEKi-induced RTKs delayed the onset 
98 
 
of MEKi resistance; however, the diversity and accumulation of the activated kinome 
response ultimately overcame the dual agents.  Induced RTK gene expression in 
response to MEKi represents an essential and global component of kinome 
reprogramming that drives drug resistance in both BL and CL tumors.  Therefore, to 
address this “kinome reprogramming dilemma”, we evaluated strategies to block 
reprogramming at a transcriptional level, with the goal of preventing the accumulation of 
kinome activity and subsequent reactivation of the targeted pathways.   
Recently, targeted inhibition of bromodomain family member BRD4 has emerged 
as a potential strategy to interfere with expression of specific oncogenes, such as 
FOSL1 and c-MYC161–163.  BRD4 is a multifunctional protein with a kinase domain and 
acetyl lysine binding activity that recruits transcriptional activators/repressors to specific 
promoters, regulating gene expression164,165.  We applied MIB/MS to determine if BRD4 
inhibition with small molecule inhibitor JQ1 could alter the activity of specific MEKi-
induced kinases in BL and CL cell lines.  Following JQ1 treatment, decreased MIB-
binding of a number of TKs from different subfamilies including EGFR, DDR1, FGFR4, 
SRC, CSK and FRK was detected in BL SUM229 cells, while reduced binding of 
PDGFRα, INSR and DDR1 occurred in SUM159 cells (Figure 5.8A).  mRNA of RTKs 
activated in response to MEKi was reduced in SUM159 cells following 48h JQ1 
treatment, consistent with inhibition of BRD4 preventing recruitment of transcriptional 
activators to RTK promoters (Figure 5.8B).   
We next tested whether targeted BRD4 inhibition with JQ1 could block MEKi-
mediated RTK reprogramming in both BL and CL cells.  Cotreatment of cells with 
GSK212 and either JQ1 or an analogous BRD4 inhibitor iBET-151 blocked induction of 
PDGFRβ, DDR1, VEGFR2 and AXL in CL cells and FGFR2, DDR1 and KIT in BL cells 
at both the RNA and protein levels (Figure 5.8C-H).  BRD4 inhibition combined with 
MEKi treatment also attenuated RTK induction in T-11 and 2225 tumor-derived cell lines, 
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exemplifying the broad effect of blocking the transcriptional component of 
reprogramming (Figure 5.8I).  siRNA-mediated BRD4 knockdown attenuated BL and CL 
MEKi reprogramming at the protein and transcript levels, confirming targeted BRD4 
inhibition as a mechanism to block kinome reprogramming to MEKi (Figure 5.8J, data 
not shown).  
 
Combination of JQ1 and GSK212 maintains growth inhibition and blocks MEKi-mediated 
selection of CL-reprogrammed cells 
The combination of MEKi and JQ1 in SUM159 cells blocked reactivation of MEK-
ERK signaling, arrested the cell cycle, and caused a strong induction of apoptotic marker 
BIM (Figure 5.9A).  MEKi-activated SRC, STAT, AKT and MEK-ERK pathways were 
also blocked by the MEKi/JQ1 combination in both SUM159 and SUM229 cells (Figure 
5.9B).  We next evaluated the ability of JQ1 to block the development of MEKi resistance 
in both TNBC BL and CL subtypes.  Cotreatment of BL and CL cells with GSK212 and 
JQ1 resulted in a significant growth inhibition over a 30-day period relative to single 
agents, preventing the development of MEKi resistance (Figure 5.9C).  Although 
HCC1806 cells appear to exhibit some resistance to the dual agent combination, growth 
inhibition in the combination of GSK212 and JQ1 was significantly enhanced relative to 
single agents.  Previous studies utilizing JQ1 have observed such differential sensitivity 
of cancer cell lines to JQ1, illustrating the plasticity of cancer cells adapting to targeted 
therapies162,163.  The MEKi/JQ1 combination blocked kinome reprogramming in sorted 
SUM229(+) and SUM229(-) cells, preventing activation of alternative downstream 
signaling, as well as the RTK-mediated reactivation of MEK-ERK pathway (Figure 
5.9D,E).  Because JQ1 attenuates MEKi-mediated BL and CL RTK reprogramming, we 
tested whether selection of CL cells could be prevented by cotreatment with MEKi/JQ1.  
Importantly, treatment of SUM229 parental cells with the GSK212/JQ1 combination 
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blocked the selection of CL SUM229(-) cells (Figure 5.9F).  These data present BRD4 
inhibition as a mechanism for blocking kinome reprogramming in both BL and CL cell 
lines to prevent adaptive resistance and the selection of CL reprogrammed cells in a 
heterogeneic model of TNBC. 
 
Discussion 
The current paradigm of the clonal evolution of tumors acknowledges that tumors 
consist of heterogeneous cancer cell populations that harbor different genomic and 
epigenetic alterations contributing to unique phenotypic characteristics12.  Our studies 
highlight the diversity of TNBC cells, revealing distinct kinome activity profiles and 
responses to MEKi between BL and CL TNBC cells.  While these subtypes are treated 
identically in the clinic, we show that the differences in kinome expression and activity 
lead to divergent molecular and phenotypic drug responses.  Indeed, unique BL and CL 
kinome responses to MEKi were observed in patient tumors through a window trial 
assessing kinome reprogramming in vivo.  While the number of patient tumors was 
limited and constraints of sample size prevented extensive analysis, these experiments 
bolster the relevance of kinome reprogramming by showing predicted RTK responses to 
MEKi in spontaneous, naturally-occurring patient tumors.  Importantly, the kinome 
reprogramming response to MEKi contributes to proliferation/survival in the presence of 
MEKi for both CL and BL cell lines, through the induction of unique RTK signatures that 
redrive growth signaling.  These signatures of induced RTKs appear to be at least 
partially aligned with subtype-specific RTK expression profiles, where highly-expressed 
subtype-specific RTKs (such as PDGFRβ in CL or FGFR2 in BL) are often responsive to 
MEKi.  It is interesting to note, however, that the CL reprogramming response to MEKi 
allows for a more consistent and robust reactivation of ERK1/2, suggesting that CL 
MEKi-responsive RTKs may be more potent activators of RAF-MEK-ERK signaling.  In 
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general, CL cells seem to exhibit greater plasticity and a more uniform signature of 
responsive RTKs, possibly due to broader heterogeneity within the BL subtype166.   
Where heterogeneous populations of BL and CL cells coexist, such as in split-
population cell lines or tumor models, the diversity in cell composition contributes to 
tumor plasticity and the acquisition of drug resistance via the selection of cancer cells 
equipped to evade drug action.  Previous studies have shown that chemotherapy 
enriches the CL phenotype from heterogeneous breast tumors, consistent with this 
subtype exhibiting greater plasticity and drug resistance10.  Here we show that selection 
of the CL phenotype also occurs in heterogeneic cell line and tumor model systems after 
MEK inhibitor treatment.  While the mechanism for the enrichment of CL cells is poorly 
understood, there are indications that the relatively robust kinome reprogramming in CL 
cells contributes to decreased drug sensitivity (though other factors undoubtedly also 
influence MEKi sensitivity)43.  In the heterogeneic SUM229 cell line, sorted CL cells 
reactivate ERK after MEKi treatment whereas sorted BL cells do not.  Consideration of 
kinome reprogramming as a mechanism for selection of resistant subpopulations adds to 
the complexity of drug response in the context of heterogeneic models.  Ultimately, the 
diversity of cell populations within a tumor and the target-specific reprogramming 
responses among these populations will determine how tumors will evolve after a given 
treatment.  With the prevalence of acquired resistance to targeted therapies coinciding 
with an apparent selection for the CL phenotype, there is a clear need to tailor 
therapeutic strategies to account for these mechanisms of resistance.   
Small, albeit synergistic, gains in growth inhibition and apoptosis can be 
achieved by small molecule inhibition of MEKi-induced RTKs in combination with MEKi.  
Unfortunately these responses are not durable, due to the dynamic nature of kinome 
reprogramming (‘the reprogramming dilemma’) and the diversity of cell populations 
within heterogeneic model systems.  Thus, we identify kinome reprogramming as a 
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mechanism of resistance and selection, but also as a vulnerability that can be exploited.  
Our goal was to develop an effective targeted therapy for TNBC that accounts for 
divergent kinome responses and prevents the selection of CL tumors, which are highly 
aggressive and refractory to conventional treatments.  We propose epigenetic inhibition 
in combination with kinase inhibitors as a global strategy to prevent kinome 
reprogramming and block CL selection. Whereas combination therapies targeting 
induced RTKs or parallel growth signaling pathways are reactionary and allow the 
accumulation of induced kinase activity, the use of epigenetic inhibitors (such as JQ1) to 
block the ability of cancer cells to respond to targeted kinase inhibition prevents kinome 
reprogramming and selection of CL cells (Figure 5.10).   Blocking the ability of cells to 
reprogram in response to targeted kinase inhibitors may transform their capacity for 
sustained tumor responses, as evidenced by the long-term inhibition of both BL and CL 
cells after cotreatment with MEKi and JQ1.  The mechanism by which BRD4 inhibition 
prevents kinome reprogramming is not completely understood, but likely lies in the 
critical role of BRD4 in supporting gene transcription at promoters, enhancers and super 
enhancers for highly expressed oncogenic kinases165,167.  Preliminary experiments with 
panobinostat suggest that HDAC inhibition and other alternative strategies (HSP90 
inhibition?) may also be employed to block kinome reprogramming.   
Despite our optimism for this epigenetic/kinase inhibitor strategy, it is prudent to 
be wary of a reprogramming response to epigenetic inhibitors that may eventually lead 
to resistant populations.  Indeed, intrinsic and acquired resistance to JQ1 has been 
observed in a variety of cell lines162,163,168.  Additionally, using MIB/MS we have identified 
a small subset of TKs and other kinases that respond to JQ1 treatment with increased 
expression/activity, raising the possibility that these may contribute to an eventual 
resistance.  However, the advantage of BRD4 inhibitors is that they cripple the ability of 
the cell to reprogram to MEKi (and likely other cytostatic/cytotoxic inhibitors), opening 
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the door for inhibitor combinations that would otherwise fail due to kinome plasticity.  Our 
data indicate that BRD4 inhibitor combinations present a promising therapeutic strategy 
for the sustained inhibition of TNBC cells, and future studies should define the 
mechanisms by which BRD4 inhibition prevents kinome reprogramming and the in vivo 
efficacy of these combinations.   
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Figure 5.1 Differential kinome reprogramming in BL and CL TNBC following MEKi. 
A) Activated MEK-ERK signaling in CL and BL patient tumors, shown by western blot.  
B) Tyrosine kinase response to 24h GSK212 (500 nM) in BL (blue) HCC1806 and CL 
(red) SUM159 TNBC cell lines.  Bar graph shows iTRAQ-determined quantitative MIB 
binding. C) MIB/MS profile of BL (blue) 2225 and CL (red) T-11 tumors in response to 35 
mg/kg AZD6244 for 2 days.  Differential induction of RTKs in response to 24h GSK212 
treatment in D) BL and E) CL TNBC cell lines as shown by western blot.  Distinct kinome 
response in F) 2225 and G) T-11 tumor and tumor-derived cell lines treated with 35 
mg/kg AZD6244 or 10 nM GSK212 for 2d, as shown by western blot.  H) qRT-PCR for 
RTK expression in BL and CL cell lines after 24h AZD6244 (5 µM).  I) RTK arrays of 
HCC1806 cells after 24h DMSO or GSK212 (100 nM).  J) RTK expression after 
continuous 30d treatment of BL HCC1806 or CL MDA231 cell lines with 10 nM GSK212.  
K,L) Colony formation in BL and CL cells following cotreatment with GSK212 and 1 µM 
BGJ398 or 250 nM sorafenib.  Quantification of staining is plotted. 
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Figure 5.2 Kinome reprogramming in patient window trial for TNBC.  A) MIB-MS 
analysis of 7 day GSK212 (1.5 mg/day) response in TNBC patient (Pt.3).  Bar graph 
shows iTRAQ-determined quantitative MIB binding as a ratio of GSK212- treated tumor 
to untreated core biopsy.  B) Inhibition of ERK activity (Pt.3, 4 and 8) and induction of 
RTKs (Pt.3 and Pt.4), in response to 7 day GSK212 treatment as shown by western blot.  
Matched untreated core biopsies were used as controls.  C) Gene expression changes 
of BL and CL MEKi response signature in TNBC patients, comparing pretreatment core 
versus GSK212-treated tumor by gene arrays.  D) Relative gene expression of core 
MEKi response signature of TNBC patients treated with GSK212 for 7 days, as 
determined by gene array.  Untreated core biopsy was used as a control for each 
patient.  E) MIB/MS binding profile of MEK-ERK pathway kinases from AZD6244-treated 
2225 and T-11 tumors.  F) MIB/MS-derived peptide ratios of MEK1 and MEK2 in Pt.1 
and 3 GSK212-treated tumors relative to untreated BL tumors.  G) MIB/MS binding 
profile of MEK-ERK pathway kinases from GSK212-treated patient tumors. The bar 
graphs show iTRAQ-determined quantitative changes in MIB binding as a ratio of 
GSK212/untreated patient tumor.  
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Figure 5.3 Distinct responses within heterogeneous cell populations.  A) Purity of 
sorting SUM229 parental cells into distinct EpCAM+/CD49f+ and EpCAM-/CD49f- 
populations using flow cytometry.  B) Quantitative comparison of SUM229 
subpopulations using MIB/MS, where line graph denotes iTRAQ-determined quantitative 
changes in MIB binding as a ratio of SUM229(EpCAM-)/SUM229(EpCAM+).  C) Distinct 
kinome reprogramming in SUM229(EpCAM+) and SUM229(EpCAM-) cells in response 
to 24h AZD6244 (5 µM) treatment, as shown by MIB/MS analysis.  Line graph shows 
iTRAQ-determined quantitative MIB binding as a ratio of AZD6244/DMSO.  D) 
Differential induction of RTK and downstream signaling in sorted SUM229(+) and 
SUM229(-) cells in response to 24h AZD6244 (5 µM) treatment, as shown by western 
blot.  E) Increased gene expression of RTKs in sorted SUM229 cells in response to 24h 
AZD6244 (5 µM), determined by qRT-PCR.   
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Figure 5.4 Prolonged MEKi treatment of BL/CL heterogeneous cell line selects for 
CL reprogrammed cells.  A) Differential MEKi sensitivity in SUM229 subpopulations, 
determined by cell counting.  B) RTK induction in SUM229 parental cells in response to 
24h GSK212 treatment.  C) FACS of SUM229 parental population continuously treated 
with 10 nM GSK212 over a 28 day period. SUM229(+) sort into quadrant Q2, while 
SUM229(-) occupy Q4. D) Western blot comparison of parental, sorted, and 30 day 
GSK212-treated SUM229 cells.  E) Western blot of 30 day GSK212-treated SUM229 
cells (SUM229-R) with increased GSK212 or GSK212 washout.  
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Figure 5.5 Treatment of C3Tag mice with MEK inhibitor enriches tumors with 
claudin-low characteristics.  A) Western blot of untreated and AZD6244-treated 
C3Tag tumors showing enrichment of CL markers and loss of BL markers after 
sustained AZD6244 treatment.  B) C3Tag tumor growth during 20 mg/kg AZD6244 
treatment.  C) MIB/MS analysis of kinases in AZD6244-treated C3Tag tumors T1-T6 
relative to untreated control tumor, showing T1-T3 and T4-T6 clustering independently.  
D) Comparison of tyrosine kinase activity in AZD6244-treated C3Tag tumors relative to 
untreated control by MIB/MS.  E) Western blot comparison of RTK response in untreated 
and AZD6244-treated C3Tag tumors.  F) C3Tag AZD6244-resistant tumors display 
kinase signaling similarities to CL T-11 mouse model by western blot. 
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Figure 5.6 Diversity of kinase activation in response to MEKi protects C3Tag 
tumors from dual agent combination therapies.  A) Western blot of C3Tag tumors 
treated with AZD6244 (20 mg/kg) and/or sorafenib (35 mg/kg) for 7d.  B) C3Tag survival 
after cotreatment with AZD6244 (20 mg/kg) and sorafenib (35 mg/kg).  C) C3Tag tumor 
growth during AZD6244 and sorafenib treatment.  D) Activation of kinase signaling 
pathways in AZD6244/sorafenib resistant tumors, as shown by western blot.  E) 
Quantitation of causes of death in C3Tag mice treated with AZD6244 and/or sorafenib.  
F) RTK arrays showing tyrosine phosphorylation of sorafenib-insensitive kinases in 
AZD6244/sorafenib resistant C3Tag tumors.  G) Activation of kinase signaling pathways 
in AZD6244/sorafenib resistant tumors, as shown by western blot.  H) MDA231 growth 
was measured by Cell-Titer Glo after 96h RNAi knockdown of RTKs, AKT, PKC or RAF1 
in the presence or absence of 1.25 µM AZD6244.  I) Growth assays of MDA231 cells 
treated with MEKi and TK inhibitor combinations. Cell growth was monitored using Cell-
Titer Glo. 
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Figure 5.7 Inability of TKIs to prevent MEK/ERK reactivation.  Schematic of TKIs 
targeting GSK212-induced RTKs, revealing inability of TKIs to completely inhibit RTK 
activity and MEK/ERK pathway reactivation. 
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Figure 5.8 Targeted BRD4 inhibition prevents MEKi mediated kinome 
reprogramming in BL and CL TNBC.  A) Inhibition of BL and CL MEKi-response 
kinases in SUM229 and SUM159 cells following 300 nM JQ1 treatment, as determined 
by MIB/MS analysis. Line graph shows iTRAQ-determined quantitative MIB binding as a 
ratio of JQ1/DMSO.  B) Decreased RNA expression of CL MEKi-response kinases 
following JQ1 treatment, quantitated by qRT-PCR. C-F) Western blot of GSK212 (10 
nM) and JQ1 (300 nM) or I-BET151 (1 µM) combination in CL (red) and BL (blue) cell 
lines.  qRT-PCR of GSK212 and JQ1 or I-BET151 combinations in G) CL and H) BL cell 
lines.  I) Western blot of CL T-11 and BL 2225 cell lines after 48h treatment with 
GSK212 (10 nM) and JQ1 (300 nM).  J) BRD4 knockdown in CL SUM159 and BL 
SUM229 cells prevents RTK induction after 48h GSK212 (10 nM) treatment, as shown 
by western blotting. 
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Figure 5.9 Combination of GSK212 and JQ1 promotes stable growth inhibition and 
prevents selection of CL cells.  A) Western blot comparison of GSK212 combinations 
in SUM159 cells.  B) Activation of downstream SRC, AKT, STAT and MEK-ERK 
signaling after 48h treatment with 10nM GSK212 and/or 300 nM JQ1 in SUM159 and 
SUM229 cells, as determined by western blot.  C) Colony formation in CL (red) and BL 
(blue) cell lines following cotreatment with GSK212 and JQ1 (200-300 nM). 
Quantification of crystal violet staining is plotted. D,E) Attenuation of RTK responses to 
GSK212 by cotreatment with JQ1 in sorted SUM229(+) and SUM229(-) populations, as 
shown by western blot. F) Crystal violet staining of SUM229 parental cells treated with 
GSK212 and 300 nM JQ1 shows inhibited selection of CL SUM229(-) cells.  
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Figure 5.10 Strategies to target kinome reprogramming.  Schematic of combination 
strategies targeting MEKi-induced kinome reprogramming in CL and BL TNBC. 
 
 
 
 
 
VI.   SIGNIFICANCE AND FUTURE DIRECTIONS 
 
The innovation of these studies lies partly in the development of technologies 
and protocols that facilitate quantitative assessment of expression and activity dynamics 
of the endogenous kinome. The development of such proteomic methods to allow 
investigation of kinome reprogramming represents a major milestone in understanding 
kinome network signaling.  MIB/MS can be used for any non-denatured protein sample 
to capture endogenous kinases, allowing for wide applicability to study diverse model 
systems.  Using our MIB/MS technique, robust kinome responses have been observed 
in a variety of models (i.e. to drug treatment in diverse cancer types, to viral infection of 
fibroblasts, and to gene knockdown in an endothelial cell model for cerebral cavernous 
malformations), illustrating the plasticity of kinome network signaling to disparate 
perturbations.  MIB/MS has provided an unbiased method to discover kinase 
dysregulation in such diverse model systems, and will certainly yield further insight into 
the mechanisms behind these and other diseases.  Importantly, MIB/MS also functions 
as a tool to investigate activity of kinase paralogs where individual reagents are lacking.  
For instance, our studies have highlighted the unique ability of MEK2 to escape inhibition 
by MEK1/2-targeted inhibitors, whereas antibody-based techniques would be unable to 
distinguish between MEK1 and MEK2 activity.   
Continual efforts are being made to improve the scalability of MIB/MS to 
accommodate small (<1mg) protein samples and increase the breadth of kinase capture.  
The addition of newly-developed pan-kinase inhibitors to the modular MIB columns could 
substantially improve the capture of expressed kinases169.  Furthermore, work is under 
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way to combine MIB enrichment with multiple reaction monitoring (MRM) to improve 
sensitivity in small samples for signature kinases170.  MRM peptides against most (or all) 
of the RTKs (or kinome?) could be developed to facilitate enhanced detection of 
underrepresented or signature kinases in patient-derived samples and other instances 
where sample size is limiting.  Successful implementation of these strategies will allow 
greater applicability of MIBs to translational samples, such as needle biopsies of tumors 
from patients participating in clinical window trials. 
There is still a great potential for MIB/MS to advance the understanding of 
kinome signaling dynamics in cancer models.  Application of these techniques to study 
kinome response to drug treatment is a novel approach to rationally design small 
molecule inhibitor combinations for the effective treatment of breast and other cancers.  
Our work has shown that cancer cells exhibit a rapid initial response to drug treatment 
that leads to kinome reprogramming and cancer cell adaptation, presenting a new mode 
of rapidly acquired drug resistance.  Specifically, we discovered that breast cancer cells 
evade growth inhibition from MEK1/2 and EGFR inhibitors by upregulating specific 
signatures of RTKs, ultimately leading to the reactivation of downstream growth 
signaling.  Kinome reprogramming is a new paradigm for drug response that highlights 
the immediate consequences of targeted inhibition in the development of drug resistance 
(Figure 6.1).  Responses to MEKi were specific to particular subtypes of TNBC, with CL 
and BL cells responding distinctly.  Our “window trial” for GSK212 confirms that kinome 
reprogramming to MEK inhibition occurs in patient tumors, underscoring the relevance of 
kinome reprogramming in vivo.  Targeting drug-induced kinases suppressed persistent 
growth signaling and substantially inhibited proliferation of cancer cells in long-term 
growth assays and tumor models.  Slight alterations to MIB/MS experimental design 
could further define kinome signaling differences by the regimen of drugs (i.e. drug 
order, dose scheduling, etc), kinase signaling at distinct subcellular localizations, or 
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subtle mechanistic difference between similar drugs.  Taken together, these studies will 
significantly impact the concept of drug resistance in cancer, and will inform scientists 
and clinicians about viable strategies for the development of effective cancer therapies.  
Future applications of MIBs could help to define other modes of kinome reprogramming 
to diverse therapeutics and in other cancer types.  For instance, our lab is now 
interested in exploring the kinome response to chemotherapeutics in TNBC, and we 
have many collaborations applying MIBs to define drug response in other cancers (CML, 
pancreatic, melanoma, etc.). 
 This work has advanced our understanding of compensatory kinase signaling 
after targeted kinase inhibitor treatment to the point where we now know that different 
strategies for effectively targeting oncogenic driver kinases are needed.  Adaptive 
resistance via kinome reprogramming compels the targeting of diverse drug-induced 
kinases to prevent growth pathway hyperactivity.  Highly induced expression and activity 
of kinases can prevent full inhibition of target kinases to bypass targeted inhibitors.  
Furthermore, subtype-specific reprogramming events facilitate the selection of drug-
resistant, kinome-reprogrammed cells from heterogeneous tumor cell populations.  
Thus, broadly targeting compensatory kinases to block induced kinase signaling will be 
extremely difficult with the current compendium of biologically active kinase inhibitors.  
We have proposed preventing kinome reprogramming as a method to preempt this form 
of adaptive resistance, aiming to exploit the transcriptional component of kinome 
reprogramming.  A variety of strategies can be envisioned to block the ability of cancer 
cells to rewire kinase growth signaling pathways, including BRD4 inhibition (exemplified 
here), HDAC inhibition through panobinostat or vorinostat, or HSP90 inhibition.  We 
have shown that this strategy works to broadly prevent reprogramming of the kinome in 
response to MEKi and gives long-term inhibition of cell proliferation, providing a proof-of-
principle and strong foundation for further preclinical studies on kinome resistance. 
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 Finally, although we have focused our work on defining induced kinases that 
support growth/survival in the presence of targeted inhibitors, a bioinformatic 
assessment of reprogramming signatures could provide information on the network 
behavior of the kinome.  A significant number of kinases exhibit reduced MIB binding 
after targeted drug treatment; while drug targets may simply be competed off the column 
by free drug, the loss of non-target kinases (as defined by in vitro assessment of the 
inhibitors ability to inhibit kinase activity) suggests pervasive network regulation of the 
kinome.  For instance, loss of cell-cycle regulating CDKs are often seen after MEKi 
treatment, indicative of slowed cell cycle progression caused by MEK/ERK loss.  
Computational analysis of kinome behavior may elucidate other unknown regulatory 
interactions within the kinome, where loss of activity for a single kinase instigates 
cascading effects to reorient the activity equilibrium of the kinome.  MIB/MS provides a 
platform for such computational analysis, where the kinome activity after specific 
perturbations can be measured and used to define the extent of kinases increasing and 
decreasing in activity.  By mapping patterns of kinase changes, undiscovered 
relationships between distinct kinases may be discovered.  Greater appreciation of how 
the kinome is “wired” could then provide more precise models of kinase signaling, 
facilitating more accurate prediction of cell signaling responses and viable kinase 
targets.  Using these methods of analysis, we can begin to unravel the dynamic nature 
of the kinome and use this information to understand and target dysregulated kinase 
signaling in cancer and other diseases. 
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Figure 6.1 The dilemma of kinome reprogramming.  This cartoon illustrates the 
adaptive response of claudin-low TNBC cells where targeted MEKi led to compensatory 
upregulation of receptor tyrosine kinases through a mechanism involving c-Myc.  This 
concept of kinome reprogramming provides a new paradigm in kinase network signaling 
and drug response. 
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